<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79076</article-id><article-id pub-id-type="doi">10.7554/eLife.79076</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Defining cellular population dynamics at single-cell resolution during prostate cancer progression</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-275603"><name><surname>Germanos</surname><given-names>Alexandre A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4677-1313</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275604"><name><surname>Arora</surname><given-names>Sonali</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275605"><name><surname>Zheng</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275606"><name><surname>Goddard</surname><given-names>Erica T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275607"><name><surname>Coleman</surname><given-names>Ilsa M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275608"><name><surname>Ku</surname><given-names>Anson T</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275609"><name><surname>Wilkinson</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267994"><name><surname>Song</surname><given-names>Hanbing</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-298304"><name><surname>Brady</surname><given-names>Nicholas J</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-248664"><name><surname>Amezquita</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275610"><name><surname>Zager</surname><given-names>Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9416-8685</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275611"><name><surname>Long</surname><given-names>Annalysa</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275612"><name><surname>Yang</surname><given-names>Yu Chi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275613"><name><surname>Bielas</surname><given-names>Jason H</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275614"><name><surname>Gottardo</surname><given-names>Raphael</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254415"><name><surname>Rickman</surname><given-names>David S</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198279"><name><surname>Huang</surname><given-names>Franklin W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5447-0436</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-143358"><name><surname>Ghajar</surname><given-names>Cyrus M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211588"><name><surname>Nelson</surname><given-names>Peter S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-23805"><name><surname>Sowalsky</surname><given-names>Adam G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2760-1853</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222339"><name><surname>Setty</surname><given-names>Manu</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-155720"><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0897-1050</contrib-id><email>ahsieh@fredhutch.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Division of Human Biology, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>University of Washington Molecular and Cellular Biology Program</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Division of Vaccine and infectious Diseases, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Division of Public Health Sciences, Translational Research Program, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Center for Data Visualization, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>University of Washington Departments of Medicine and Genome Sciences</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Translational Data Science Integrated Research Center, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Division of Basic Sciences, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sharifi</surname><given-names>Nima</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Cleveland Clinic</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79076</elocation-id><history><date date-type="received" iso-8601-date="2022-03-29"><day>29</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-27"><day>27</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-03-04"><day>04</day><month>03</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.02.482711"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79076-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79076-figures-v2.pdf"/><abstract><p>Advanced prostate malignancies are a leading cause of cancer-related deaths in men, in large part due to our incomplete understanding of cellular drivers of disease progression. We investigate prostate cancer cell dynamics at single-cell resolution from disease onset to the development of androgen independence in an in vivo murine model. We observe an expansion of a castration-resistant intermediate luminal cell type that correlates with treatment resistance and poor prognosis in human patients. Moreover, transformed epithelial cells and associated fibroblasts create a microenvironment conducive to pro-tumorigenic immune infiltration, which is partially androgen responsive. Androgen-independent prostate cancer leads to significant diversification of intermediate luminal cell populations characterized by a range of androgen signaling activity, which is inversely correlated with proliferation and mRNA translation. Accordingly, distinct epithelial populations are exquisitely sensitive to translation inhibition, which leads to epithelial cell death, loss of pro-tumorigenic signaling, and decreased tumor heterogeneity. Our findings reveal a complex tumor environment largely dominated by castration-resistant luminal cells and immunosuppressive infiltrates.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>prostate cancer</kwd><kwd>PTEN</kwd><kwd>Single cell RNAseq</kwd><kwd>mRNA Translation</kwd><kwd>epithelial cells</kwd><kwd>immune microenvironment</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R37 CA230617</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01 GM135362</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P50 CA097186</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Peter S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000861</institution-id><institution>Burroughs Wellcome Fund</institution></institution-wrap></funding-source><award-id>1012314.02</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012394</institution-id><institution>Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>T32 CA080416</award-id><principal-award-recipient><name><surname>Germanos</surname><given-names>Alexandre A</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>Department of Defense</institution></institution-wrap></funding-source><award-id>BCRP W81XWH-19-1-0076</award-id><principal-award-recipient><name><surname>Goddard</surname><given-names>Erica T</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P01 CA163227</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Peter S</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA234715</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Peter S</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nelson</surname><given-names>Peter S</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30 CA015704</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>S10 OD028685</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019329</institution-id><institution>Emerson Collective</institution></institution-wrap></funding-source><award-id>691630</award-id><principal-award-recipient><name><surname>Hsieh</surname><given-names>Andrew C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A large-scale single-cell RNA sequencing experiment explores single-cell dynamics in epithelial and immune populations within murine prostates upon cancer initiation and progression and validates key findings across orthogonal models and patient specimens.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Prostate cancer is the most diagnosed malignancy and second leading cause of cancer-related death in men in the United States (<xref ref-type="bibr" rid="bib69">Siegel et al., 2021</xref>). This is largely due to the development of treatment resistant disease termed castration resistant prostate cancer (CRPC). Historically, CRPC has been considered a singular disease entity. However, this viewpoint has significantly evolved with the advent of next generation sequencing and the characterization of many distinct etiologies (<xref ref-type="bibr" rid="bib78">Watson et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Bluemn et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Labrecque et al., 2019</xref>). Intratumoral heterogeneity is also common in prostate cancer, as several studies have highlighted both the complex cellular architecture of the prostate and multiple potential cell-of-origin models (<xref ref-type="bibr" rid="bib25">Goldstein et al., 2010</xref>; <xref ref-type="bibr" rid="bib68">Shen and Abate-Shen, 2010</xref>). For instance, while prostate epithelial cells canonically present as either basal cells or highly differentiated luminal cells, a distinct, more stemlike luminal population (<italic>Psca+/Krt4+/Tacstd2+</italic>) that primarily resides in the proximal prostate has previously been described (<xref ref-type="bibr" rid="bib80">Xin et al., 2005</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Korsten et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Kwon et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Sackmann Sala et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">McAuley et al., 2019</xref>). While the nomenclature for this cell type has varied, most studies have observed a similar set of biomarkers and characteristics, including increased stemlike and inflammatory/immunogenic signatures (<xref ref-type="bibr" rid="bib51">Liu et al., 2016</xref>). These cells also appear to be castration-resistant; indeed, some studies show canonical prostatic luminal cells may undergo phenotype switching towards a more stemlike <italic>Krt4+</italic> cell state in castrate conditions, reverting and helping repopulate the prostate during castration and regeneration cycles (<xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Mevel et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Kwon et al., 2021</xref>).</p><p>This novel cell type was further verified using lineage tracing and single-cell technologies (<xref ref-type="bibr" rid="bib51">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Crowley et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Joseph et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Kwon et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Mevel et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). <italic>Krt4+</italic> cells are also found more rarely in the distal prostate, where they localize to invagination tips (<xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). These cell types remain incompletely characterized, including in their origin; some studies point to proximal luminal cells originating from the urethra, and therefore not being prostatic in nature (<xref ref-type="bibr" rid="bib35">Joseph et al., 2020</xref>). Others recognize the presence of urethral cells but draw a distinction between them and prostatic <italic>Krt4+</italic> proximal cells (<xref ref-type="bibr" rid="bib17">Crowley et al., 2020</xref>).</p><p>There is evidence that <italic>Krt4</italic> + cells may contribute to tumor initiation in the prostate (<xref ref-type="bibr" rid="bib80">Xin et al., 2005</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Korsten et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Kwon et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Sackmann Sala et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). For instance, several studies find these cells enriched in precancerous lesions upon genetic perturbations in murine models (<xref ref-type="bibr" rid="bib76">Wang et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Korsten et al., 2009</xref>). Additionally, proximal cells appear less able to contribute to tumor initiation than those residing in distal prostate lobes (<xref ref-type="bibr" rid="bib41">Korsten et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). These findings, combined with studies characterizing the role of <italic>Krt4+</italic> cells in castration and regeneration, suggest they may contribute to treatment resistance in advanced cancer. However, this has yet to be established in CRPC models.</p><p>While tumor heterogeneity contributes to treatment resistance, another source of poor clinical outcomes can be found in the consistent lack of response of CRPCs to immunotherapy. Prostate cancer has generally been described as ‘immune-cold’ due to the presence of multiple immunosuppressive cell types (<xref ref-type="bibr" rid="bib71">Stultz and Fong, 2021</xref>). For example, tumor infiltration by myeloid-derived suppressor cells (MDSCs) has been implicated as an immunosuppressive phenotype (<xref ref-type="bibr" rid="bib23">Garcia et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Lopez-Bujanda et al., 2021</xref>). Metastatic CRPC also responds poorly to immune checkpoint inhibition and other immunotherapies (<xref ref-type="bibr" rid="bib12">Cham et al., 2020</xref>). This has been confirmed clinically with autologous active cellular immunotherapy which only demonstrated a small (~4 month) improvement in survival in patients (<xref ref-type="bibr" rid="bib36">Kantoff et al., 2010</xref>). Therefore, characterizing the immune microenvironment in advanced prostate cancer may be crucial to better understand this disease and inform potential therapeutic vulnerabilities or combinatorial strategies.</p><p>Here, we have created an atlas of prostate cellular composition and phenotypic evolution through tumor initiation, progression, and hormone independence using a <italic>Pten</italic> loss murine model as an archetype. We observe a dramatic expansion of an intermediate luminal cell type in cancer and link this epithelial population to treatment resistance in multiple human cohorts. We also characterize increased pro-tumorigenic immune cell recruitment and define cell-cell signaling patterns that contribute to lymphoid and myeloid cell expansion. In addition, using a tissue-specific transgenic model, we demonstrate that cell type specific protein synthesis is essential for the maintenance of tumor heterogeneity in both basal and intermediate cells in the context of AR-low prostate cancer. Finally, we make our data available for further study through an interactive portal, with the aim of providing a broad resource for the cancer research community. Together, our findings highlight the cell type-specific and patient relevant features of prostate cancer progression and demonstrate the utility of single-cell technologies to uncover novel cell-specific paradigms of treatment resistance.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Characterization of WT and Pten<sup>fl/fl</sup> ventral prostates at single cell resolution</title><p>To determine the cellular architecture of prostate cancer initiation, we conducted single-cell RNA sequencing (scRNAseq) of the ventral prostates of 6-month-old wild-type (WT) and <italic>PB-Cre4;Pten<sup>fl/fl</sup>;ROSA26-rtTA-IRES-eGFP</italic> (herein referred to as <italic>Pten<sup>fl/fl</sup></italic>, see Methods) prostate cancer mice (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We chose the ventral lobe because it has been well-characterized throughout prostate cancer progression at a deep molecular level and for the abundance of cellular populations (<xref ref-type="bibr" rid="bib33">Hsieh et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Hsieh et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Liu et al., 2019</xref>). In the <italic>Pten<sup>fl/fl</sup></italic> model, exon 5 of the tumor suppressor <italic>Pten</italic> is deleted within basal and luminal epithelial cells of the prostate and mice uniformly develop prostate cancer (<xref ref-type="bibr" rid="bib75">Wang et al., 2003</xref>). PTEN is a negative regulator of the oncogenic PI3K-AKT-mTOR signaling pathway, which is deregulated in nearly all advanced prostate cancer patients (<xref ref-type="bibr" rid="bib73">Taylor et al., 2010</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Proliferative split in basal cancer cells enables expansion of intermediate cells.</title><p>(<bold>A</bold>) Simplified schematic of single-cell RNA sequencing of WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates. (<bold>B</bold>) UMAP of WT and <italic>Pten<sup>fl/fl</sup></italic> epithelial cells. Left, both conditions superposed; middle, WT only; right, <italic>Pten<sup>fl/fl</sup></italic> only. Epithelial cell types are demarcated by color (red = basal, light blue = luminal progenitor, dark blue = intermediate, green = differentiated). (<bold>C</bold>) Relative abundance of epithelial cells in WT (n=3) and <italic>Pten<sup>fl/fl</sup></italic> (n=2) mice. Y-axis shows the % composition of each sample by cell type (***p&lt;0.001, negative binomial test). Data presented as +/-SD. (<bold>D</bold>) Top GSEA results enriched in <italic>Pten<sup>fl/fl</sup></italic> compared to WT for each epithelial subtype. Intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> were compared to luminal progenitor cells in WT. All pathways are enriched with FDR &lt;0.05. (<bold>E</bold>) Proliferation signature (CCP) composite score in epithelial cells, clustered by condition (Data presented as +/-SD, *p&lt;0.05, n.s.=not significant, permutation test). N/A indicates missing data due to no cells being present in the condition. WT n=3, <italic>Pten</italic><sup><italic>fl/fl</italic></sup> n=2. (<bold>F</bold>) UMAP visualization of cell cycle phase assignment per cell, showing % cells in non-G1 (S or G2/M) (black border = WT basal cells, blue border = hypo-proliferative basal cells in <italic>Pten<sup>fl/fl</sup>,</italic> and red border = hyper-proliferative basal cells in <italic>Pten<sup>fl/fl</sup></italic>. *p&lt;0.05, chi-square test). (<bold>G</bold>) GSEA between hyper- and hypo-proliferative basal clusters in <italic>Pten<sup>fl/fl</sup></italic>. All pathways are enriched with FDR &lt;0.05. (<bold>H</bold>) RNA velocity analysis of <italic>Pten<sup>fl/fl</sup></italic> epithelial cells; highlighted section shows intersection of basal and intermediate cells. (<bold>I</bold>) Pseudotime trajectories drawn by Palantir through the basal and intermediate compartments, with hypo-proliferating basal cells as the designated start point. (<bold>J</bold>) Expression of important cell fate and differentiation regulators along basal-intermediate trajectory.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Epithelial cells contain published subtypes and urethral cells.</title><p>(<bold>A</bold>) UMAP visualization of all cells in WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates, colored and labeled by cell ID. (<bold>B</bold>) Violin plots of <italic>rtTA-eGFP</italic> transgene expression. Left, transgene expression in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. Right, expression in <italic>Pten<sup>fl/fl</sup></italic> cell types. (<bold>C</bold>) Heatmap of composite scores of published prostate epithelial subtype signatures in basal, urethral, luminal progenitor, and differentiated cells in WT mice (left). Dot plot of epithelial biomarker gene expression in WT mice (right). (<bold>D</bold>) UMAP visualization of epithelial cells in WT prostates, colored and labeled by cell ID. (<bold>E</bold>) UMAP visualization of epithelial cells in <italic>Pten<sup>fl/fl</sup></italic> prostates, colored and labeled by cell ID. (<bold>F</bold>) UMAP visualization of published intermediate cell biomarkers in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. (<bold>G</bold>) UMAP visualization of urethral, luminal progenitor, and intermediate cells in WT and <italic>Pten<sup>fl/fl</sup></italic> mice, colored and labeled by cell ID. (<bold>H</bold>) UMAP visualization of <italic>Psca</italic>, pan-epithelial and luminal biomarkers in urethral, luminal progenitor, and intermediate cells in WT and <italic>Pten<sup>fl/fl</sup></italic> mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Basal proliferation is subset-specific and intermediate cells express luminal markers.</title><p>(<bold>A</bold>) Bar plot of cell cycle phase assignments in WT basal cells and <italic>Pten<sup>fl/fl</sup></italic> hyper- and hypo-proliferative basal cells. (<bold>B</bold>) Bar plot of CCP signature composite score in WT (n=3) basal cells and <italic>Pten<sup>fl/fl</sup></italic> (n=2) hyper- and hypo-proliferative basal cells (Data presented as +/-SD). (<bold>C</bold>) Trajectory analysis of <italic>Pten<sup>fl/fl</sup></italic> epithelial cells. (<bold>D</bold>) Top 3000 highly variable genes in <italic>Pten<sup>fl/fl</sup></italic> basal and intermediate cells, clustered by expression pattern along the basal-intermediate (top) or hypo-proliferative basal-hyper-proliferative basal (bottom) trajectories drawn via Palantir (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). (<bold>E</bold>) UMAP visualization of luminal biomarkers in epithelial cells in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. Black circles indicate luminal-intermediate transition zone.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Quality control and filtering (read count thresholds and excluding cells with high mitochondrial content) resulted in transcriptomes from 24,079 total cells across five samples (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A-C</xref>). Using SingleR, we identified epithelial, stromal, and immune cell types (<xref ref-type="bibr" rid="bib4">Aran et al., 2019</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). To confirm that the epithelial cells in the <italic>Pten<sup>fl/fl</sup></italic> model underwent Cre-mediated recombination, we measured the frequency of <italic>rtTA-eGFP</italic> fusion mRNA in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. The <italic>rtTA-eGFP</italic> transcript was present in 14.5% of <italic>Pten<sup>fl/fl</sup></italic> epithelial cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Given that on average ~1200 genes/cell were detected and ~24,000 genes were identified overall, we expect the average transcript to be found in ~5% of cells in the dataset. Therefore, our finding suggests widespread recombination, and therefore loss of <italic>Pten</italic>, within the epithelial compartment. Importantly, recombination was not observed in WT mice or non-epithelial cell types (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><p>We further defined the epithelial population in WT mice via signatures and biomarkers obtained from the Strand (Basal, Urethral, and VP), Sawyers (Basal, L1, and L2), and Xin (Sca-1+) groups (<xref ref-type="bibr" rid="bib35">Joseph et al., 2020</xref>; <xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Liu et al., 2016</xref>). We found canonical basal (<italic>Krt5+/Sox4+</italic>) and luminal (<italic>Nkx3-1+/Sbp+</italic>) cells, as well as two distinct clusters expressing luminal progenitor markers (<italic>Psca+/Tactsd2+/Krt4+</italic>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C–D</xref>). These clusters were mainly distinguished by different basal, L2, and luminal (VP/L1) signature scores. In addition, one cluster clearly expressed previously identified urethral markers <italic>Aqp3</italic> and <italic>Ly6d</italic>, and was negative for other progenitor markers (<italic>Ppp1r1b, Clu;</italic> <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib17">Crowley et al., 2020</xref>). Accordingly, we designated this cluster as urethral. The other <italic>Krt4+</italic> cluster likely represents progenitor prostatic cells, either from the proximal or distal prostate (<xref ref-type="bibr" rid="bib17">Crowley et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). Therefore, we refer to this cluster as luminal progenitor hereafter (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>).</p><p>We then examined epithelial cell subtypes in <italic>Pten<sup>fl/fl</sup></italic> mice. We identified basal, urethral, and canonical luminal cells, as well as a large cluster of cells similar to WT luminal progenitor cells, characterized by expression of <italic>Krt4/Tacstd2/Ppp1r1b</italic> but not <italic>Psca</italic> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E–F</xref>). Clustering urethral cells with luminal progenitor and this new <italic>Pten<sup>fl/fl</sup></italic> cluster, we find that the urethral cells cluster apart from the other cell types and express significantly lower levels of prostate luminal or pan-epithelial markers (<italic>Krt8, Krt18, Epcam</italic>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G–H</xref>). This supports the hypothesis that we have identified both urethral and prostate cells, and likely indicates a prostatic origin for the <italic>Pten<sup>fl/fl</sup></italic> cluster. We designated <italic>Krt4+/Tacstd2+/Ppp1r1b+</italic> cells in <italic>Pten<sup>fl/fl</sup></italic> mice as ‘intermediate’ cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>).</p></sec><sec id="s2-2"><title><italic>Pten</italic> loss generates differentially proliferating populations and a dominance of intermediate luminal cell states from multiple cellular origins</title><p>Next, we sought to determine how the epithelial compartment is remodeled in the context of tumor initiation. We excluded the urethral cluster because it is not prostatic in origin and therefore is less likely to significantly impact cellular dynamics in prostate cancer. We observed a dramatic increase in the proportion of intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> mice compared to luminal progenitor abundance in the WT setting (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>). To investigate potential mechanisms of this expansion of the intermediate population, we identified differentially expressed genes (DEG) and performed gene set enrichment analysis (GSEA) on each epithelial subtype, comparing the WT and <italic>Pten<sup>fl/fl</sup></italic> epithelial compartments (<italic>Pten<sup>fl/fl</sup></italic> basal:WT basal, <italic>Pten<sup>fl/fl</sup></italic> intermediate:WT luminal progenitor, <italic>Pten<sup>fl/fl</sup></italic> luminal:WT luminal) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1D</xref>). We noted enrichment of oncogene and tumor suppressor pathways in the <italic>Pten<sup>fl/fl</sup></italic> mice, including upregulation of AKT and mTOR, which are expected in this model. We also observed increased <italic>Wnt</italic> signaling and metabolic processes across all epithelial cell types. Interestingly, both epithelial cell migration and proliferation were enriched in most epithelial cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These findings suggest that intermediate cell expansion could be mediated by increased proliferation of luminal progenitors, or by increased transdifferentiation of other cell types, which has been widely characterized in WT settings (<xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Mevel et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Kwon et al., 2021</xref>).</p><p>To evaluate the possibility of increased proliferation of different epithelial cell types, we used the Cell Cycle Progression (CCP) score, a proliferation gene signature developed and validated in human prostate cancer patients (<xref ref-type="bibr" rid="bib18">Cuzick et al., 2011</xref>), and generated a composite score (see Materials and methods) in our dataset. Surprisingly, while there was a significant increase in CCP score in basal cells in <italic>Pten<sup>fl/fl</sup></italic> mice compared to WT, we observed no significant change in intermediate cells compared to luminal progenitor cells (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). To further characterize epithelial proliferation, we performed cell cycle scoring, assigning one of three phases (G1, G2/M, or S) to each cell in the dataset, and found a striking split in the basal compartment of <italic>Pten<sup>fl/fl</sup></italic> mice, but not WT mice (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1E</xref>). In <italic>Pten<sup>fl/fl</sup></italic> mouse prostates, 18.6% of basal cells were hyper-proliferative, with 99.7% of these cells in a proliferative phase (G2/M or S phases). The rest of the basal compartment only had 52.2% of cells in a G2/M or S phase, lower than WT basal cells (68.5%) (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). We also verified that the increase in basal cell CCP score was specifically due to this hyper-proliferative cluster (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). One possibility for this differential increase in basal cell proliferation is higher Cre-mediated recombination efficiency in some clusters over others. We analyzed transgene abundance in our basal subclusters and found that in the <italic>Pten<sup>fl/fl</sup></italic> mouse, 13.6% (12.0%–15.7%) of hypo-proliferating and 19.6% (19.1%–20.3%) of hyper-proliferating basal cells express the <italic>rtTA-eGFP</italic> transgene. This &lt;1.5-fold difference does not account for the &gt;twofold increase in cycling cells, or the ~threefold increase in CCP score observed between the subclusters. As such, we conclude that <italic>Pten</italic> loss in the murine prostate promotes a dual phenotype in basal cells, with most cells displaying decreased proliferation while a subset becomes hyper-proliferative.</p><p>We further characterized the basal subclusters in <italic>Pten<sup>fl/fl</sup></italic> mice by performing DEG analysis followed by GSEA (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1F</xref>). As expected, we observed several cell-cycle-related pathways enriched in the hyper-proliferative cluster. However, the hypo-proliferative basal cluster was enriched for several migration, development, and differentiation signatures (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Transdifferentiation of basal cells to luminal cells in the context of malignant transformation has previously been reported in prostate cancer (<xref ref-type="bibr" rid="bib25">Goldstein et al., 2010</xref>; <xref ref-type="bibr" rid="bib14">Choi et al., 2012</xref>; <xref ref-type="bibr" rid="bib54">Lu et al., 2013</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2013</xref>). As such, we hypothesized that the hypo-proliferative basal subcluster might transition into intermediate luminal cells, thus providing one potential mechanism for the expansion of this cell type in the absence of increased proliferation. To verify this, we generated pseudotime trajectories using Monocle3 (<xref ref-type="bibr" rid="bib11">Cao et al., 2019</xref>), which confirmed a direct path from hypo-proliferative basal cells to intermediate luminal cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). We also performed RNA velocity, a technique to visualize differentiation dynamics on a per cell basis (<xref ref-type="bibr" rid="bib49">La Manno et al., 2018</xref>). This analysis revealed significant movement from hypo-proliferative, but not hyper-proliferative basal cells to intermediate cells (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). Finally, we used a pseudotime algorithm (<xref ref-type="bibr" rid="bib66">Setty et al., 2019</xref>) to identify two potential trajectories starting from the hypo-proliferative basal cells and ending either in the hyper-proliferative basal cluster or in the intermediate luminal cell compartment (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). We generated clusters of genes with similar expression patterns across these pseudotime axes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>) and performed GSEA on the clusters. We found that several genes involved in cell fate decisions including <italic>Pdgfb</italic>, <italic>Trp63</italic>, and <italic>Shh</italic> are highly expressed early but rapidly decrease over the trajectories. Conversely, genes implicated in differentiation such as <italic>Notch1</italic> increased over the basal-intermediate path, but not the basal-basal path (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). This suggests that hypo-proliferating basal cells strongly express development markers associated with cell fate choice, but these genes are not expressed in hyper-proliferative basal cells or intermediate cells. Moreover, intermediate cells express higher levels of differentiation-associated genes than either basal subcluster. Together, these findings support the idea that hypo-proliferative basal cells transdifferentiate into intermediate luminal cells during tumorigenesis, while the basal compartment may be replenished by a hyper-proliferative, non-differentiating population.</p><p>Multiple studies have suggested that prostate luminal cells can phenotype switch to intermediate-like states under conditions such as castration (<xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). To verify whether luminal populations may contribute to the intermediate cell state, we plotted the expression of genes canonically expressed in prostate luminal cells and found that while luminal cells did express these genes most strongly, there was overlap with a population of intermediate cells immediately adjacent to the luminal cells in <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). This suggests that luminal cells may phenotype switch into an intermediate state and retain some identity markers in the context of <italic>Pten</italic> loss. It is also possible that luminal progenitor cells contribute to the intermediate population, as <italic>Krt4+</italic> cells within the proximal and distal prostate have been described as tumor initiating cells after <italic>Pten</italic> loss (<xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>). Overall, our findings support multiple cells of origin for <italic>Krt4+</italic> intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> mice, including phenotype switching of basal and luminal cells, as well as potential expansion of luminal progenitor cells. In vivo lineage tracing studies using highly precise Cre-drivers will likely be necessary to fully disentangle the cellular origins of intermediate cell states in the <italic>Pten<sup>fl/fl</sup></italic> prostate cancer model.</p></sec><sec id="s2-3"><title>Immune infiltration increases in <italic>Pten</italic><sup><italic>fl/fl</italic></sup> mice and is pro-tumorigenic</title><p>Our GSEA of all three epithelial cell types showed an enrichment for immune-related pathways in <italic>Pten<sup>fl/fl</sup></italic> mice, suggesting increased immunogenic signaling relative to WT mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To determine the impact of epithelial <italic>Pten</italic> loss on immune cells, we calculated the relative abundance of immune cells in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. We found that T cells, macrophages, neutrophils, and dendritic cells were all significantly expanded in the <italic>Pten<sup>fl/fl</sup></italic> mouse; in fact, only B cells were not expanded compared to WT (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–B</xref>). Immune infiltration has previously been characterized as immunosuppressive in PTEN null prostate tumors (<xref ref-type="bibr" rid="bib23">Garcia et al., 2014</xref>). Therefore, we expected these expanding immune populations to be immunosuppressive and therefore pro-tumorigenic. To test this hypothesis, we assigned activation states or subtypes to immune cells based on known biomarkers (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–E</xref>). First, we characterized the neutrophil population as myeloid-derived suppressor cells (MDSCs) based on published biomarkers (<xref ref-type="bibr" rid="bib2">Alshetaiwi et al., 2020</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). We also found three macrophage cell states: tumor-associated macrophages (TAMs), M2-activated macrophages, and M1-activated macrophages. Interestingly, the M1 cells expressed the AR-dependent markers <italic>Sbp</italic> and <italic>Defb50</italic> and as a result, we termed them tissue-resident macrophages (TRM, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Finally, we characterized three T cell subtypes: CD8<sup>+</sup> T cells, gamma-delta T cells, and natural killer T (NKT) cells. CD8<sup>+</sup> and gamma-delta T cells expressed the markers of exhaustion and immunosuppression <italic>Pdcd1</italic> and <italic>Ctla4</italic>, suggesting their cytotoxic activity may be dampened in the context of <italic>Pten</italic> loss (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). All these cell types except for NKT cells and TRMs are expanded in <italic>Pten<sup>fl/fl</sup></italic> mice, implying a potential role for these immune cells in establishing or maintaining a pro-tumorigenic prostate tumor microenvironment (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Immune recruitment in <italic>Pten<sup>fl/fl</sup></italic> prostates is mediated by both epithelial and immune cell signaling.</title><p>(<bold>A</bold>) Top immune-related GSEA results enriched in <italic>Pten<sup>fl/fl</sup></italic> compared to WT mice for each epithelial subtype. All pathways are enriched with FDR &lt;0.05. (<bold>B</bold>) UMAP visualization of immune cells labeled by cell subtype or state. (<bold>C</bold>) Relative abundance of immune cells in WT (n=3) and <italic>Pten<sup>fl/fl</sup></italic> (n=2) mice. Y-axis shows the % composition of each sample by cell type (Data presented as +/-SD, ***p&lt;0.001, n.s.=not significant, negative binomial test). (<bold>D</bold>) Dot plot of signaling interactions between macrophages and epithelial cells. Y-axis, ligand-receptor pairs from CellphoneDB database. X-axis, cell-cell pairings. Interactions are directional: the first gene in a pair is expressed in the first cell in the cell-cell interaction. (<bold>E</bold>) Dot plot of epithelial ligand and macrophage receptor gene expression in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. (<bold>F</bold>) Dot plot of <italic>Ccr1</italic> and <italic>Ccr1</italic> ligand expression in MDSCs and macrophages in WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates. MDSCs are only present in <italic>Pten<sup>fl/fl</sup></italic> and therefore do not have a WT row (denoted by asterisk). (<bold>G</bold>) Plot of signaling interactions between CD8 +T cells and epithelial cells and macrophages. (<bold>H</bold>) Dot plot of CD8<sup>+</sup> T cell receptors and epithelial and macrophage ligand gene expression in WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Immune cells contain pro-tumorigenic subtypes and macrophages are recruited by fibroblast signaling.</title><p>(<bold>A</bold>) UMAP of immune cells in WT and <italic>Pten<sup>fl/fl</sup></italic> prostates, labeled by cell types. (<bold>B</bold>) Relative abundance of immune cell types in WT (n=3) and <italic>Pten<sup>fl/fl</sup></italic> (n=2) mice (***p&lt;0.001, n.s.=not significant, negative binomial regression test). (<bold>C</bold>) Heatmap of immune cell type biomarker expression in WT and <italic>Pten<sup>fl/fl</sup></italic> mice; neutrophil cells express MDSC markers. Log-transformed read counts. (<bold>D</bold>) Heatmap of marker expression in macrophage cell subtypes. Log-transformed read counts. (<bold>E</bold>) Heatmap of marker expression in T cell subtypes. Log-transformed read counts. (<bold>F</bold>) Plot of ligand-receptor interactions between fibroblast and macrophage subtypes. (<bold>G</bold>) Dot plot of <italic>Ccr2</italic> ligand expression in fibroblasts in WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates. (<bold>H</bold>) Dot plot of <italic>Ccr2</italic> expression in macrophage subtypes in WT and <italic>Pten<sup>fl/fl</sup></italic> ventral prostates. (<bold>I</bold>) Dot plot of signaling interactions between epithelial cells and MDSCs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig2-figsupp1-v2.tif"/></fig></fig-group><p>M2 macrophages, TAMs, and MDSCs are generally pro-tumorigenic (<xref ref-type="bibr" rid="bib82">Zaynagetdinov et al., 2011</xref>; <xref ref-type="bibr" rid="bib13">Chanmee et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Garcia et al., 2014</xref>). Together with exhausted CD8<sup>+</sup> T cells, this suggests a broadly pro-tumorigenic immune environment. We hypothesized that cell-cell signaling originating from tumor epithelial cells may play an important role in recruiting immune cells to the prostate. To probe cell-cell interactions in our system, we used a ligand-receptor database and interaction algorithm that classifies the strength of specific ligand-receptor interactions between cell groups (Efremova et a., 2020). We found key interactions between epithelial subtypes and M2 macrophages and TAMs, such as interactions targeting the <italic>Cd74</italic> receptor, that point to active recruitment (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Ligands in the epithelial basal, intermediate, and differentiated cell populations were more highly expressed in <italic>Pten<sup>fl/fl</sup></italic> mice than in WT mice, which corresponds to the increased macrophage abundance in <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>Additionally, we observed increased <italic>Ccl2/7/11-Ccr2</italic> interactions between fibroblasts and M2/TAMs upon <italic>Pten</italic> loss, suggesting that fibroblasts in prostate cancer may also play an active role in macrophage recruitment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). <italic>Ccl2/7/11</italic> are all significantly upregulated in <italic>Pten<sup>fl/fl</sup></italic> fibroblasts (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>). Interestingly, <italic>Ccr2</italic> is expressed highly in M2 and TAMs in cancer, but not in TRMs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1H</xref>). The lack of fibroblast signaling to TRMs provides a possible cellular explanation for the lower abundance of this macrophage subtype in <italic>Pten<sup>fl/fl</sup></italic> mice compared to WT. Another possibility is that TRMs polarize and transition into M2/TAM macrophages, potentially in response to epithelial signaling. Overall, these findings highlight a role for epithelial cells and fibroblasts in recruiting pro-tumorigenic macrophages to the prostate in the context of <italic>Pten</italic> loss.</p><p>While we observed significant epithelial to macrophage signaling, the top interactions between epithelial cells and MDSCs were characterized by receptors expressed in epithelial cells and ligands expressed in MDSCs. As such, it is unlikely that epithelial cells are responsible for the expansion of MDSCs in the prostate (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>). Instead, we noted increased expression of the <italic>Ccr1</italic> receptor in MDSCs, and a concomitant increase in <italic>Ccl6/7/8/9</italic> expression in M2 macrophages. These genes are known <italic>Ccr1</italic> ligands (<xref ref-type="bibr" rid="bib40">Korbecki et al., 2020</xref>), which suggests that MDSCs are recruited by M2-activated macrophages (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Interestingly, <italic>Ccl6/7/8/9</italic> are not expressed in TRMs or TAMs, highlighting the specificity of M2-MDSC signaling.</p><p>Finally, we examined interactions between epithelial cells and T cells. We found both attractive (<italic>Cxcr6-Cxcl16</italic>) and pro-exhaustion (<italic>Pdcd1-Fam3c</italic>) interactions between CD8<sup>+</sup> T cells and epithelial cells. We found these same interactions between macrophages and CD8<sup>+</sup> cells, as well as <italic>Cd86-Ctla4</italic>/<italic>Cd28</italic> interactions (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). <italic>Ctla4</italic> and <italic>Cd28</italic> belong to the same family of T cell co-stimulator receptors. <italic>Ctla4</italic> has a suppressive effect while <italic>Cd28</italic> is activating, and both receptors are targeted by the <italic>Cd86</italic> ligand (<xref ref-type="bibr" rid="bib24">Gmünder and Lesslauer, 1984</xref>; <xref ref-type="bibr" rid="bib64">Salomon and Bluestone, 2001</xref>; <xref ref-type="bibr" rid="bib8">Boesteanu and Katsikis, 2009</xref>). These findings imply a synergistic signaling pattern with both tumor epithelia and macrophages recruiting and mitigating the cytotoxicity of T cells. We noted that TAMs exhibited particularly robust expression of <italic>Cxcl16</italic> and <italic>Cd86</italic>, suggesting that similar to M2-mediated MDSC recruitment, TAMs may specifically be responsible for modulating T-cell abundance and function (<xref ref-type="fig" rid="fig2">Figure 2H</xref>).</p><p>Overall, our data suggests that pro-tumorigenic macrophages are recruited by epithelial and fibroblast signaling in <italic>Pten</italic> null tumors. These macrophages then assist tumor signaling in remodeling the immune environment, including recruiting and exhausting cytotoxic CD8<sup>+</sup> T cells and attracting pro-tumorigenic MDSCs. Given ligand expression data, M2 macrophages may be mainly responsible for MDSC recruitment and TAMs for CD8<sup>+</sup> T cell recruitment. These findings reveal a complex signaling system with multiple coordinated sources of ligand expression working in tandem to build a microenvironment favorable to tumor escape from immunological suppression.</p></sec><sec id="s2-4"><title>Castration-induced intermediate cell heterogeneity drives resistance to androgen deprivation</title><p>Having examined epithelial and immune populations in prostate cancer initiation, we sought to determine how these cells reorganize over the course of castration resistance. It has been shown that castration of <italic>Pten<sup>fl/fl</sup></italic> mice leads to the emergence of AR-low tumors (<xref ref-type="bibr" rid="bib52">Liu et al., 2019</xref>). As such, we conducted scRNAseq in 6 months old <italic>Pten<sup>fl/fl</sup></italic> mice with and without castration at 4 months of age and evaluated the changes that occurred in the epithelial compartment (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Castration caused the intermediate luminal cell population to expand while the differentiated luminal cells disappeared entirely (<xref ref-type="fig" rid="fig3">Figure 3B–C</xref>). We hypothesized that androgen deprivation may differentially affect epithelial subtypes. To investigate this, we generated an AR activity score using a 20-gene signature (<xref ref-type="bibr" rid="bib31">Hieronymus et al., 2006</xref>) and found that WT luminal progenitor cells had high AR activity, but <italic>Pten<sup>fl/fl</sup></italic> intermediate cells exhibited very low AR activity in both intact and castrated <italic>Pten</italic>-null conditions. On the contrary, differentiated luminal cells retained high AR activity in <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This suggests that loss of <italic>Pten</italic> in intermediate luminal cells decreases their reliance on AR signaling and induces expansion of this compartment upon castration. While it is possible that castration is lethal to differentiated luminal cells, previous studies have shown that they are able to phenotype switch into an intermediate state in AR-low conditions (<xref ref-type="bibr" rid="bib37">Karthaus et al., 2020</xref>). Therefore, it is likely that this increase in intermediate cell abundance in <italic>Pten<sup>fl/fl</sup></italic> castrate mice is due to lineage plasticity in luminal cells. Notably, there were no significant changes in proliferation between the intact and castrate conditions in basal or intermediate cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Intermediate cells are primed for survival and diversification in the context of castration.</title><p>(<bold>A</bold>) Simplified schematic of setup for single-cell sequencing of <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> castrated (cx) ventral prostates. (<bold>B</bold>) Split UMAP visualizations of <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup></italic> cx epithelial cells. (<bold>C</bold>) Relative abundance of epithelial cells in <italic>Pten<sup>fl/fl</sup></italic> intact (n=2) and cx (n=3) prostates. Y-axis shows the % composition of each sample by cell type (Data presented as +/-SD, ***p&lt;0.001, n.s.=not significant, negative binomial test). (<bold>D</bold>) Androgen Receptor (AR) gene signature composite score in epithelial cells, clustered by condition (Data presented as +/-SD, *p&lt;0.05, permutation test). N/A indicates missing data due to no cells being present in the condition. WT n=3, <italic>Pten</italic><sup><italic>fl/fl</italic></sup> intact n=2, <italic>Pten</italic><sup><italic>fl/fl</italic></sup> cx n=3. (<bold>E</bold>) UMAP visualization of intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> intact and cx prostates. Left, colored by condition; right, colored by clusters 0–5. (<bold>F</bold>) Relative abundance of intermediate clusters. Top, intact <italic>Pten<sup>fl/fl</sup></italic>(n=2); bottom, <italic>Pten<sup>fl/fl</sup></italic> cx (n=3) (Data presented as +/-SD). (<bold>G</bold>) Heatmap of composite score for AR, CCP, and Reactome translation gene signatures in intermediate clusters. (<bold>H</bold>) Heatmap of composite score for AR, CCP, and Reactome translation gene signatures in WT intact and castrate basal and luminal cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Castration-resistant intermediate cells are phenotypically diverse.</title><p>(<bold>A</bold>) Composite score of CCP signature in WT, <italic>Pten<sup>fl/fl</sup></italic> intact, and <italic>Pten<sup>fl/fl</sup></italic> cx epithelial cells (Data presented as +/-SD, *p&lt;0.05, permutation test) (<bold>B</bold>) Heatmap of top differentially expressed genes across intermediate clusters 0–5. Blue arrows, basal markers; green arrows, AR-dependent genes; red arrows, ribosomal or translation machinery genes. (<bold>C</bold>) Top GSEA results for genes upregulated in intermediate clusters 1 and 4. All pathways are enriched with FDR &lt;0.05. (<bold>D</bold>) Heatmap of ribosomal gene expression in basal cells in <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> cx mice. (<bold>E</bold>) UMAP visualization of AR signaling status in intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> cx mice. (<bold>F</bold>) Relative abundance of intermediate cells with high, medium, or low AR signaling in <italic>Pten<sup>fl/fl</sup></italic> intact (n=2) and <italic>Pten<sup>fl/fl</sup></italic> cx (n=3) mice (Data presented as +/-SD, *p&lt;0.05, ***p&lt;0.001, negative binomial regression test). (<bold>G</bold>) UMAP visualization of epithelial cells in WT intact, WT cx, <italic>Pten<sup>fl/fl</sup></italic> intact, and <italic>Pten<sup>fl/fl</sup></italic> cx mice, colored and labeled by cell ID.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Given the increase in intermediate cells associated with castration resistant tumor growth, we next asked how castration modulates phenotypic diversity in this population. We isolated and re-clustered intermediate cells from <italic>Pten<sup>fl/fl</sup></italic> intact and castrated mice and found six distinct clusters (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). The majority of intact <italic>Pten<sup>fl/fl</sup></italic> intermediate cells (62.8%) congregated in a single cluster (cluster 3), while castrated <italic>Pten<sup>fl/fl</sup></italic> intermediate cells were widely distributed over four unique groups (clusters 0, 1, 2, and 4) (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). DEG analysis showed high expression of AR-dependent genes <italic>Sbp</italic>, <italic>Defb50</italic>, and <italic>Spink1</italic> in cluster 3, suggesting this cell population may have high AR signaling activity relative to other intermediate cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>, <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3A-F</xref>). This cluster represents cells close to differentiated luminal cells on the epithelial UMAP (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and may indicate a luminal origin that could explain retaining high AR activity. Similarly, we observed high expression of the basal cell markers <italic>Krt5</italic> and <italic>Krt15</italic> in cluster 1 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>; this cluster corresponds to the intermediate cells proximal to basal cells on the epithelial UMAP (<xref ref-type="fig" rid="fig3">Figure 3B</xref>)). This supports our hypothesis that some intermediate cells are derived from basal transdifferentiation in the context of cancer, while others may have luminal origins. We also noted multiple ribosomal genes upregulated in clusters 1 and 4, suggesting increased translational signatures in these clusters (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). GSEA confirmed enrichment of multiple translation pathways in clusters 1 and 4 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). We also investigated whether castration leads to increased translational signatures in basal cells. We found that several genes encoding ribosomal proteins were overexpressed in castrated basal cells compared to intact <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Together, these findings demonstrate that castration promotes increased heterogeneity of the intermediate cell populations and potentially diversifies cell-type-specific translation dependence in both basal and intermediate cells in the context of <italic>Pten</italic> loss.</p><p>To further characterize the functional differences in castration resistant intermediate cells, we generated AR activity, proliferation, and translation scores for each intermediate cell cluster. We found a gradient of residual AR signaling activity, with cluster 3 having the highest score (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Importantly, proliferation and translation activity scores were inversely correlated with AR signaling, with clusters 1 and 4 exhibiting high proliferation and translation scores and low AR scores (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). We designated the clusters as AR-high, -medium, or -low and noted that intact <italic>Pten<sup>fl/fl</sup></italic> mouse prostates contain mostly AR-high intermediate cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–F</xref>). Upon castration the number of AR-medium and -low cells increase substantially (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–F</xref>). These findings suggest that castration may select for lower AR expressing cell types with high proliferation, but also conserve some ‘intact-like’ regions with relatively high AR activity and low proliferation. We also conclude that AR activity in intermediate cells may be correlated with cell of origin, as clusters expressing basal markers (clusters 1 and 4) exhibit low AR activity while cluster 3, which expresses luminal markers, has AR activity comparable to differentiated luminal cells (<xref ref-type="fig" rid="fig3">Figure 3G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Given these correlations, an alternate hypothesis might be that increased basal transdifferentiation, rather than a selection event, is responsible for the increased abundance of AR-low intermediate cells. Lineage-tracing experiments evaluating proliferation and transdifferentiation differences between intact and castrated <italic>Pten<sup>fl/fl</sup></italic> mice will be necessary to fully establish a mechanism for increasing AR-low intermediate cell populations.</p><p>Our findings raise the question of what aspects of intermediate cell heterogeneity are driven by castration versus loss of <italic>Pten</italic>? To address this question, we performed single-cell RNA sequencing on 9 WT castrated mouse prostates, which we binned into three replicates to overcome small tissue yields due to atrophy in castrated WT prostates. We found that non-basal cells in WT castrate mice aggregate into one clustered region separate from both WT intact luminal cells and <italic>Pten<sup>fl/fl</sup></italic> intermediate cells, but interestingly were closest to WT luminal progenitor cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). We evaluated the changes in AR activity, translation, and proliferation in basal and luminal cells between WT intact and castrated cells. We found that similar to <italic>Pten<sup>fl/fl</sup></italic> intermediate cells, lower AR activity was associated with an increase in a translation signature. However, unlike the <italic>Pten<sup>fl/fl</sup></italic> intermediate cells we observed a decrease in the proliferation signature (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). These findings demonstrate that castration plays an important role in translational heterogeneity in intermediate cells. However, the change in proliferation is likely related to loss of <italic>Pten</italic>.</p></sec><sec id="s2-5"><title>Castrate intermediate cell signature correlates with advanced prostate cancer and worse patient outcomes</title><p>Given the widespread use of the <italic>Pten<sup>fl/fl</sup></italic> model (<xref ref-type="bibr" rid="bib19">Ding et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Svensson et al., 2011</xref>; <xref ref-type="bibr" rid="bib33">Hsieh et al., 2012</xref>; <xref ref-type="bibr" rid="bib23">Garcia et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Hsieh et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Ku et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Allott et al., 2018</xref>; <xref ref-type="bibr" rid="bib3">Antoch et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Morel et al., 2021</xref>; <xref ref-type="bibr" rid="bib62">Quaglia et al., 2021</xref>) and our new understanding of cellular dynamics in the context of disease progression, we sought to determine which cell type and context most closely correlated with human prostate cancers that went on to resist androgen deprivation therapy (ADT). To this end, we used a gene signature of ADT resistance derived from human prostate tumors prior to treatment with ADT plus the AR inhibitor enzalutamide, in a neoadjuvant setting (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) (NCT02430480) (<xref ref-type="bibr" rid="bib38">Karzai et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Wilkinson et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Ku et al., 2021</xref>). We generated DEG lists for each epithelial cell type (basal, intermediate, luminal) comparing WT and <italic>Pten<sup>fl/fl</sup></italic> or <italic>Pten<sup>fl/fl</sup></italic> intact and castrated prostates and performed enrichment analysis using the ADT resistance signature. Out of all the cell types, castrated intermediate cells compared to intact intermediate cells exhibited the most enrichment for the resistance signature (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The top five genes from the resistance signature that were upregulated in castrated intermediate cells were <italic>ATP1B1</italic>, <italic>BST2</italic>, <italic>CP</italic>, <italic>IGFBP3</italic>, and <italic>PTTG1</italic>. Importantly, these genes were downregulated in cluster 3 of our intact intermediate cells compared to castrate clusters, demonstrating specificity for aggressive disease (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Furthermore, all five genes were upregulated in human tumors that exhibited pathologic resistance to ADT (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Lastly, we sought to investigate whether these genes were associated with worse outcomes for prostate cancer patients. We examined disease-free survival (DFS) of patients stratified by high or low expression of the five top genes across two major prostate cancer cohorts (<xref ref-type="bibr" rid="bib60">Network, 2015</xref>; <xref ref-type="bibr" rid="bib73">Taylor et al., 2010</xref>). We found that patients whose tumor samples expressed high levels of any of these five enriched genes experienced significantly shorter disease-free survival (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). We also analyzed patients with <italic>PTEN</italic> loss or PI3K/AKT pathway dysregulation from the TCGA dataset and found the same trend (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). These results suggest that the castrate intermediate cell state in the <italic>Pten<sup>fl/fl</sup></italic> may correlate with poor patient outcomes.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Intermediate cells are enriched for a signature of treatment resistance that correlates with advanced human disease.</title><p>(<bold>A</bold>) Diagram of clinical trial used to establish gene signature of androgen deprivation treatment resistance (NCT02430480). (<bold>B</bold>) Enrichment plot of ADT resistance gene signature relative to intermediate cell DEGs between <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup></italic> cx (adjusted p-value = 0.00381). (<bold>C</bold>) Kaplan-Meier curve of disease-free survival for prostate cancer patients in TCGA database with or without high RNA expression of top correlated genes from <bold>B</bold>. Red line, patients with normal expression of all genes; blue line, patients with expression of at least 1 gene with TPM (transcripts per million) in the 80th percentile or above. (<bold>D</bold>) UMAP of tumor cells from human patient samples. Red, primary cancer; blue, metastatic cancer. (<bold>E</bold>) UMAP visualization of per-cell computed score for 5-gene signature from (<bold>B-C</bold>) in human cancer samples. (<bold>F</bold>) UMAP visualization of per-cell computed score for 5-gene signature from (<bold>B-C</bold>) in PR and PRN mouse models. Pie charts indicate proportion of cells with zero, low, intermediate, or high signature scores. (<bold>G</bold>) Stacked bar chart showing proportion of cells from PR or PRN mice in each scoring category for the 5-gene signature.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>5 Genes expressed in intermediate cells correlate with poor disease outcomes in human patients.</title><p>(<bold>A</bold>) Heatmap of top 5 resistance genes in intermediate clusters, labeled by AR status and condition (intact or castrate). (<bold>B</bold>) Heatmap of the top 5 genes enriched in castrated intermediate cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) and their expression in ADT non-responder (NR), intermediate responder (IR), and excellent responder (ER) patients. (<bold>C</bold>) Kaplan-Meier curve of disease-free survival of patients in the <xref ref-type="bibr" rid="bib73">Taylor et al., 2010</xref> cohort, separated by expression of the top 5 resistance genes in castrated intermediate cells. Red line, normal expression of top 5 genes; blue line, patients with expression of at least 1 gene with TPM in the 80th percentile or above. (<bold>D</bold>) Kaplan-Meier curve of disease-free survival of patients in the TCGA database, filtered for PTEN loss or PI3K/AKT pathway dysregulation, separated by expression of the top 5 resistance genes in castrated intermediate cells. Red line, normal expression of top 5 genes; blue line, patients with expression of at least 1 gene with TPM (transcripts per million) in the 80th percentile or above.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Given our finding that a 5-gene signature derived from castrate intermediate cells correlates to human clinical phenotypes, we investigated if this signature is enriched in metastatic disease. We integrated single-cell RNA sequencing data from primary prostate cancers (n=11) (<xref ref-type="bibr" rid="bib70">Song et al., 2022</xref>) and metastatic prostate cancers (n=6) (<xref ref-type="bibr" rid="bib20">Dong et al., 2020</xref>) and found that primary and metastatic cells clustered separately (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). We generated a composite score of our 5-gene signature on a per-cell basis and visualized it on the UMAP. We observed an enrichment of the signature only in metastatic patients (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Importantly, the cluster containing this signature was composed of cells from five out of the six metastatic samples. These findings show that our 5-gene signature is enriched in human metastatic prostate cancer.</p><p>Finally, a possible confounding factor in this model is that physical castration of the <italic>Pten<sup>fl/fl</sup></italic> model alone could be driving the expression of the 5-gene signature. To investigate this, we examined single-cell sequencing data from an orthogonal non-castrated mouse model of cancer progression (<xref ref-type="bibr" rid="bib9">Brady et al., 2021</xref>). This study used prostate specific autochthonous models including a double knockout <italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup></italic> mouse (PR) and a triple mutant <italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup>/Nmyc<sup>+</sup></italic> mouse (PRN). PRN mice generate prostate tumors with significantly stronger castration resistance compared to PR mice (<xref ref-type="bibr" rid="bib9">Brady et al., 2021</xref>). Single-cell RNA sequencing data in this study was produced without castration in both PR and PRN mice, resulting in a model of cancer progression outside of physical castration. We overlaid our 5-gene resistance signature on UMAPs of both mouse models and found strong enrichment of the signature in PRN mice compared to PR mice (<xref ref-type="fig" rid="fig4">Figure 4F–G</xref>). These results reveal that the 5-gene signature is likely not driven by castration alone. Together, our findings demonstrate that a gene signature generated through a specific cell-type within murine prostate cancer closely correlates with human CRPC and worse outcomes in patients.</p></sec><sec id="s2-6"><title>Androgen deprivation decreases immune cell abundance but activates <italic>Tnf</italic> signaling</title><p>Androgen deprivation induces a host of physiological changes in the prostate, including modulations of immune signaling (<xref ref-type="bibr" rid="bib67">Sha et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Lopez-Bujanda et al., 2021</xref>). Having observed significant epithelial changes in castrated <italic>Pten<sup>fl/fl</sup></italic> mice, we next investigated the consequences of castration on the immune environment. We observed a significant decline in the abundance of all 3 macrophage subtypes, as well as CD8<sup>+</sup> T cells, relative to intact <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5A–B</xref>). We performed ligand-receptor interaction analysis to understand how androgen deprivation disrupts cell-cell signaling patterns (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). We found that epithelial signaling to macrophage cells was still intact, with relatively little change in ligand or receptor expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–B</xref>). However, the <italic>Ccl2/7/11-Ccr2</italic> signaling axis from fibroblasts to M2 macrophages and TAMs was entirely ablated in castrated <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). <italic>Ccr2</italic> expression was significantly decreased in macrophages, and <italic>Ccl2/7/11</italic> were all dramatically decreased in fibroblasts (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This suggests that fibroblast-mediated macrophage recruitment is interrupted by androgen deprivation. Indeed, androgen signaling is known to promote pro-tumorigenic macrophage function as well as macrophage recruitment via <italic>Ccr2</italic> expression, lending credence to this hypothesis (<xref ref-type="bibr" rid="bib48">Lai et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Cioni et al., 2020</xref>; <xref ref-type="bibr" rid="bib6">Becerra-Diaz et al., 2020</xref>). TRMs also decreased in abundance, but they were not targeted by fibroblast signaling and epithelial signaling was uninterrupted. Given the expression of AR-dependent genes in this macrophage subtype (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>), we speculated that loss of androgen signaling could be deleterious to this population. Indeed, in intact <italic>Pten <sup>fl/fl</sup></italic> mice TRMs had high AR activity relative to other macrophage subtypes, and this activity was decreased by castration (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). This suggests that castration interrupts fibroblast-mediated pro-tumorigenic M2 and TAM recruitment and depletes the androgen-dependent tissue-resident macrophage reservoir, leading to decreased macrophage abundance in the prostate.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Castration remodels immune environment via fibroblast signaling and increases TNF pathway activity.</title><p>(<bold>A</bold>) Combined UMAP visualization of immune cells in <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup></italic> cx ventral prostates. (<bold>B</bold>) Relative abundance of immune cells in <italic>Pten<sup>fl/fl</sup></italic> intact (n=2) and cx (n=3) mice. Y-axis shows the % composition of each sample by cell type (Data presented as +/-SD, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, n.s=not significant, negative binomial test). (<bold>C</bold>) Dot plot of signaling interactions between macrophages and fibroblasts. (<bold>D</bold>) Dot plot of <italic>Ccr2</italic> expression in M2 macrophages and TAMs (left). Dot plot of <italic>Ccr2</italic> ligand expression in fibroblasts in <italic>Pten<sup>fl/fl</sup></italic> intact and cx mice (right). (<bold>E</bold>) Dot plot of signaling interactions between CD8<sup>+</sup> T cells and epithelial and macrophage cells in <italic>Pten<sup>fl/fl</sup></italic> intact and cx mice. (<bold>F</bold>) Dot plot of epithelial and macrophage ligands and CD8<sup>+</sup> T cell receptor gene expression in <italic>Pten<sup>fl/fl</sup></italic> intact and cx mice. (<bold>G</bold>) Dot plot of <italic>Tnf</italic> signaling interactions between myeloid and epithelial/fibroblast cells in <italic>Pten<sup>fl/fl</sup></italic> intact and cx prostates. (<bold>H</bold>) Scatter plot of TCGA PRAD study patient signature composite scores. Y-axis, TNF signaling signature score; X-axis, AR signaling signature score (Pearson’s correlation).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Epithelial-mediated macrophage recruitment is not interrupted by castration.</title><p>(<bold>A</bold>) Plot of signaling interactions between macrophage subtypes and epithelial cells in <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> cx prostates. (<bold>B</bold>) Dot plot of epithelial ligand and macrophage receptor gene expression in <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> cx ventral prostates. (<bold>C</bold>) Composite score of AR signaling signature in macrophage subtypes in <italic>Pten<sup>fl/fl</sup></italic> intact and <italic>Pten<sup>fl/fl</sup></italic> cx prostates (Data presented as +/-SD). (<bold>D</bold>) Scatter plot of TCGA PRAD study patient signature composite scores, filtered for patients harboring PTEN mutations. Y-axis, TNF signaling signature score; X-axis, AR signaling signature score (Pearson’s correlation).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Macrophages likely contribute to CD8<sup>+</sup> T cell recruitment in intact <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2G–H</xref>); we speculated that macrophage-mediated signaling might be interrupted in the context of castration and cause a decrease in CD8<sup>+</sup> T cell abundance. Indeed, while epithelial-CD8<sup>+</sup> interactions were mostly intact, <italic>Cd86-Cd28/Ctla4</italic> signaling from M2 macrophages and TAMs was disrupted, and <italic>Cd86</italic> expression was greatly reduced in both M2s and TAMs (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). In addition, receptor expression was decreased in CD8<sup>+</sup> T-cells, including suppressive markers <italic>Ctla4</italic> and <italic>Pdcd1</italic> (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). These findings suggest that depletion of the macrophage population causes a decrease in both CD8<sup>+</sup> T cell recruitment and suppression, possibly leading to more cytotoxic but less abundant CD8<sup>+</sup> T cells in castrated <italic>Pten<sup>fl/fl</sup></italic> mice.</p><p>Finally, <italic>Tnf</italic> signaling has previously been implicated as a pro-tumorigenic factor in AR low prostate cancer (<xref ref-type="bibr" rid="bib58">Mizokami et al., 2000</xref>; <xref ref-type="bibr" rid="bib67">Sha et al., 2015</xref>). Accordingly, we examined <italic>Tnf</italic> interactions in our ligand-receptor analysis and found a striking enrichment of <italic>Tnf</italic> pathway activity in castrated mice. Specifically, pro-tumorigenic myeloid cells (M2 macrophages, TAMs, and MDSCs) expressing <italic>Tnf</italic> interact with multiple receptors in epithelial cells and fibroblasts (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). To investigate whether this association held true in human prostate cancer, we correlated a 200 gene signature of <italic>Tnf</italic> activity (<xref ref-type="bibr" rid="bib27">Griss et al., 2020</xref>) with AR signaling activity in the prostate cancer TCGA dataset (<xref ref-type="bibr" rid="bib60">Network, 2015</xref>). We found a significant inverse correlation between TNF and AR activity in human patients, validating our finding that TNF signaling is induced in prostate cancer upon castration (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). This correlation also held true when only considering patients with PTEN loss (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). We conclude that castration in the <italic>Pten<sup>fl/fl</sup></italic> mouse provokes several large-scale cellular signaling changes that result in decreased macrophage and CD8<sup>+</sup> T cell populations and increased <italic>Tnf</italic> signaling.</p></sec><sec id="s2-7"><title>Translation inhibition in AR-low prostate cancer is lethal to basal and intermediate cells and disrupts pro-tumorigenic signaling</title><p>Deregulated mRNA translation rates have previously been implicated in aberrant gene expression and aggressive AR-low prostate cancer in the <italic>Pten<sup>fl/fl</sup></italic> mouse (<xref ref-type="bibr" rid="bib52">Liu et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Lim et al., 2021</xref>). However, understanding how the per cell requirement for aberrant translation enables tumor heterogeneity has been technically challenging. Therefore, it remains to be determined which prostate cancer epithelial cell types require increased translation for androgen independent growth. Given the strong correlation between proliferation and translation observed in both basal and intermediate cells (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), we hypothesized that inhibiting translation in the <italic>Pten<sup>fl/fl</sup></italic> mouse could be deleterious to both cell types. To investigate this possibility, we used the <italic>PB-Cre4;Pten<sup>fl/fl</sup>;ROSA26-rtTA-IRES-eGFP;TetO-</italic>4ebp1<sup>M</sup> mouse model (herein referred to as <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup>). In this model, Cre-mediated recombination leads to <italic>Pten</italic> loss and expression of the rtTA protein in both basal and intermediate cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). When mice are treated with doxycycline, a mutant <italic>Eif4ebp1</italic> transgene (4ebp1<sup>M</sup>) is expressed (<xref ref-type="bibr" rid="bib34">Hsieh et al., 2015</xref>). eIF4EBP1 is a negative regulator of translation initiation and functions via inhibition of eIF4F complex assembly (<xref ref-type="bibr" rid="bib65">Schuster and Hsieh, 2019</xref>). This mutant allele cannot be inactivated via mTOR-mediated phosphorylation and its expression robustly inhibits eIF4F complex formation and translation initiation in prostate epithelia (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Using this model, we sought to determine the epithelial cell type specific dependencies of castration resistant prostate cancer. Here, doxycycline was administered starting at 4 months of age, simultaneously with castration, and prostates were collected at 6 months of age.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>4EBP1<sup>M</sup> expression is lethal in epithelial cells and decreases EGFR and TNF ligands in epithelial cells and fibroblasts.</title><p>(<bold>A</bold>) Simplified schematic of the eIF4F translation initiation complex and how the 4EBP1<sup>M</sup> protein functions in the <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mouse model when treated with doxycycline. (<bold>B</bold>) UMAP visualization of epithelial cells in <italic>Pten<sup>fl/fl</sup></italic> cx and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx prostates, colored by genotype. (<bold>C</bold>) Violin plot of <italic>rtTA-eGFP</italic> transgene expression in epithelial cells in each <italic>Pten<sup>fl/fl</sup></italic> condition. Plot shows only cells expressing the transgene; each dot represents a cell. Percentages represent the proportion of transgene-positive cells in each condition. (<bold>D</bold>) Dot plot of top GSEA results from DEG analysis of transgene-positive basal cells in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice compared to <italic>Pten<sup>fl/fl</sup></italic> cx ventral prostates. All pathways are enriched with FDR &lt;0.05. (<bold>E</bold>) Dot plot of <italic>Tnf</italic> signaling interactions between myeloid and epithelial/fibroblast cells in <italic>Pten<sup>fl/fl</sup></italic> cx and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice. (<bold>F</bold>) Dot plot of <italic>Tnf</italic> and <italic>Tnf</italic> ligand expression in myeloid cells, epithelial cells, and fibroblasts in <italic>Pten<sup>fl/fl</sup></italic> cx and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx prostates. Red boxes highlight ligands with decreased expression in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice. (<bold>G</bold>) Plot of <italic>Egfr</italic> signaling interactions between epithelial cells and fibroblasts in <italic>Pten<sup>fl/fl</sup></italic> intact, <italic>Pten<sup>fl/fl</sup></italic> cx, and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx prostates. (<bold>H</bold>) Dot plot of <italic>Egfr</italic> and <italic>Egfr</italic> ligand expression in epithelial cells and fibroblasts in <italic>Pten<sup>fl/fl</sup></italic> intact, <italic>Pten<sup>fl/fl</sup></italic> cx, and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx ventral prostates. Red boxes highlight ligands with decreased expression in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Interactive Portal, Enabling Gene- and Cell- Specific Comparisons Across the Spectrum of Prostate Cancer Initiation and Progression in vivo.</title><p>Interactive website can be found at <ext-link ext-link-type="uri" xlink:href="https://atlas.fredhutch.org/hsieh-prostate/">https://atlas.fredhutch.org/hsieh-prostate/</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79076-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Initially, no major differences were observed in the UMAP comparing all epithelial cells in castrated <italic>Pten <sup>fl/fl</sup></italic> mice with or without 4ebp1<sup>M</sup> (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). However, we noted a striking (~10-fold) depletion of the <italic>rtTA-eGFP</italic> transgene which is required for 4ebp1<sup>M</sup> induction in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> basal and intermediate epithelial cells compared to the <italic>Pten<sup>fl/fl</sup></italic> model (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). We hypothesized that translation inhibition in AR-low prostate cancer might be lethal or confer a competitive disadvantage to AR low epithelial cells, and that the bulk of the remaining epithelia did not express the 4ebp1<sup>M</sup> and were simply castrate cells that did not express the transgene. To test this hypothesis, we performed DEG analysis only on transgene-positive cells, comparing castrated cells with or without 4ebp1<sup>M</sup>. We found many more differentially expressed genes between these groups in basal cells (465 differentially expressed genes) than in the non-filtered analysis (56 DEGs) (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5A-B</xref>). We did not observe a significant change in the number of DEGs between castrated <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> intermediate cells when filtering for <italic>rtTA-eGFP</italic>+ cells. This may be due to the high phenotypic diversity in this compartment and the very low proportion of transgene-positive intermediate cells after 4ebp1<sup>M</sup> induction (&lt;1%, <xref ref-type="table" rid="table1">Table 1</xref>) causing a lack of robustness in the DEG analysis.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Transgene abundance in PTEN mouse epithelia.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="2">Cell Type</th><th align="left" valign="top"><italic>Pten<sup>fl/fl</sup></italic></th><th align="left" valign="top"><italic>Pten<sup>fl/fl</sup></italic> cx</th><th align="left" valign="top"><italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2">Basal</td><td align="left" valign="top">All</td><td align="char" char="." valign="top">1795</td><td align="char" char="." valign="top">2718</td><td align="char" char="." valign="top">1565</td></tr><tr><td align="left" valign="top"><italic>rtTA-eGFP</italic>+</td><td align="char" char="." valign="top">255<break/>(<italic>14.2%</italic>)</td><td align="char" char="." valign="top">422<break/>(<italic>15.5%</italic>)</td><td align="char" char="." valign="top">41<break/>(<italic>2.6%</italic>)</td></tr><tr><td align="left" valign="top" rowspan="2">Intermediate</td><td align="left" valign="top">All</td><td align="char" char="." valign="top">2391</td><td align="char" char="." valign="top">8230</td><td align="char" char="." valign="top">4760</td></tr><tr><td align="left" valign="top"><italic>rtTA-eGFP</italic>+</td><td align="char" char="." valign="top">438<break/>(<italic>18.3%</italic>)</td><td align="char" char="." valign="top">1073<break/>(<italic>13.0%</italic>)</td><td align="char" char="." valign="top">43<break/>(<italic>0.90%</italic>)</td></tr></tbody></table></table-wrap><p>Interestingly, upon performing pathway analysis on basal cell DEGs we found enrichment of pathways relating to translation, cell cycle arrest, and apoptosis, and observed downregulation of mitochondrial function and mTORC1 signaling pathways (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). These findings suggest that remaining transgene-positive basal cells in the <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mice may be undergoing cell cycle arrest, interruption of growth processes such as inhibition of the mTOR pathway, and apoptosis. We also noted that in the basal compartment, the proportion of hyperproliferative cells had decreased drastically (<xref ref-type="table" rid="table2">Table 2</xref>). This suggests that highly proliferative basal cells are more dependent upon high translation than less proliferative basal cells.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Basal proliferative subset proportions in <italic>rtTA-eGFP+</italic> cells.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Basal Subset</th><th align="left" valign="top">Hypo-proliferative</th><th align="left" valign="top">Hyper-proliferative</th></tr></thead><tbody><tr><td align="left" valign="top"><bold><italic>Pten<sup>fl/fl</sup></italic></bold></td><td align="char" char="." valign="top">188 (<italic>73.7%</italic>)</td><td align="char" char="." valign="top">60 (<italic>23.5%</italic>)</td></tr><tr><td align="left" valign="top"><bold><italic>Pten<sup>fl/fl</sup></italic> cx</bold></td><td align="char" char="." valign="top">313 (<italic>74.1%</italic>)</td><td align="char" char="." valign="top">98 (<italic>23.2%</italic>)</td></tr><tr><td align="left" valign="top"><bold><italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup></bold></td><td align="char" char="." valign="top">38 (<italic>97.4%</italic>)</td><td align="char" char="." valign="top">1 (<italic>2.6%</italic>)</td></tr></tbody></table></table-wrap><p>Given the large-scale changes in epithelial populations caused by 4ebp1<sup>M</sup> induction in castrated <italic>Pten<sup>fl/fl</sup></italic> mice, we next asked how cell-cell signaling between the remaining epithelial cells and other compartments were affected by the loss of basal and intermediate cell populations through translation inhibition (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5C</xref>). We found that <italic>Tnf</italic> signaling was greatly decreased between myeloid and epithelial cells (<xref ref-type="fig" rid="fig6">Figure 6E–F</xref>). In addition, epithelial-fibroblast and inter-epithelial <italic>Egfr</italic> signaling also decreased significantly (<xref ref-type="fig" rid="fig6">Figure 6G–H</xref>). <italic>Egfr</italic> activity is associated with worse cancer prognosis, and inhibition of <italic>Egfr</italic> signaling has been proposed as a therapeutic approach in advanced prostate cancer (<xref ref-type="bibr" rid="bib39">Kim et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Guérin et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Xiong et al., 2020</xref>). Overall, these findings show that both basal and intermediate cancer cell types require increased translation initiation to maintain castration resistance and that aberrant mRNA translation is required for tumor heterogeneity. Furthermore, translation inhibition of distinct epithelial populations can impact the local tumor microenvironment.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we demonstrated that <italic>Pten</italic> deletion in mouse prostate epithelial cells results in the generation of an intermediate luminal subtype, which is phenotypically similar to but likely distinct from the <italic>Psca</italic>+/<italic>Krt4+/Tacstd2+</italic> luminal progenitor populations in the WT prostate. In this model, the <italic>Pten<sup>fl/fl</sup></italic> intermediate cells likely derive from three cellular pools: basal cells, luminal progenitor cells, and differentiated luminal cells. Our findings support the idea that basal cells can transdifferentiate into intermediate cells upon loss of <italic>Pten</italic>. This corresponds well with lineage tracing studies (<xref ref-type="bibr" rid="bib14">Choi et al., 2012</xref>; <xref ref-type="bibr" rid="bib77">Wang et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Lu et al., 2013</xref>) that showed that basal cells can be cells of origin for prostate cancer and transition to luminal phenotypes during transformation in mice. We also identify common luminal markers expressed in some intermediate cells, suggesting luminal cells may also phenotype switch to an intermediate state upon <italic>Pten</italic> loss. Lastly, the close proximity of luminal progenitor cells to intermediate cells and the fact they can express AR and form neoplasia in the context of <italic>Pten</italic> loss (<xref ref-type="bibr" rid="bib29">Guo et al., 2020</xref>) reveal another potential source of intermediate cells. Our study is limited by the fact that the Cre driver is active in all epithelial subtypes. To observe transdifferentiation or phenotype switching, cell type specific lineage tracing will be required. New techniques such as DNA Typewriter may offer flexible multiplexed platforms to track multiple cell lineages in the same system simultaneously (<xref ref-type="bibr" rid="bib15">Choi et al., 2022</xref>).</p><p>We observed that intermediate cells undergo significant cell state changes upon castration which increases their heterogeneity. This heterogeneity is characterized by a spectrum of AR signaling inversely correlated with both proliferation and translation activity. Within this spectrum, clusters with high AR activity and low proliferation and translation express some luminal markers, while low AR, high proliferation, high translation clusters express basal markers. This finding supports the hypothesis that both basal and luminal cells can transdifferentiate to intermediate cells in cancer and suggests that basal-originating intermediate cells may represent more aggressive cancer phenotypes. These specific intermediate clusters may be responsible for the increased tumor growth previously observed at the whole-prostate level in castrated <italic>Pten<sup>fl/fl</sup></italic> mice (<xref ref-type="bibr" rid="bib52">Liu et al., 2019</xref>). This lends importance to the question of whether increased AR-low intermediate populations in <italic>Pten<sup>fl/fl</sup></italic> castrate mice are due to the expansion of an existing cell state, or renewed lineage plasticity events from basal cells. Comparative lineage tracing experiments measuring basal transdifferentiation and proliferation dynamics in intact and castrated <italic>Pten<sup>fl/fl</sup></italic> mice will be necessary to fully address this question. Overall, we speculate that the intermediate cell compartment is highly heterogeneous in <italic>Pten<sup>fl/fl</sup></italic> mice partly due to multiple cellular origins converging on a common phenotype.</p><p>We further characterize the effects of intermediate cell expansion by showing that a 5-gene signature enriched in this cell type correlates with poor patient outcomes, advanced human CRPC, and castration resistance in an orthogonal mouse model. Specifically, we observe that upregulation of these 5 genes significantly correlates with shorter disease-free survival in two datasets of bulk RNA-seq from patients. We also find that the 5-gene signature is specifically enriched in a subset of metastatic, but not primary, human prostate cancer cells (<xref ref-type="bibr" rid="bib70">Song et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Dong et al., 2020</xref>). Finally, we demonstrate the enrichment of the signature in an orthogonal murine model of prostate cancer progression and castration resistance (<xref ref-type="bibr" rid="bib9">Brady et al., 2021</xref>). Our findings suggest that intermediate cells are enriched for a gene signature of treatment resistance in human tumors and pose the intriguing question of whether detection of this population in patients can provide a useful prognostic tool. Further in vivo studies will be necessary to validate the role of intermediate cell states in human disease and their potential implications in clinical medicine.</p><p>The prostate tumor environment is typically described as immunosuppressive and does not readily respond to immunotherapies (<xref ref-type="bibr" rid="bib36">Kantoff et al., 2010</xref>; <xref ref-type="bibr" rid="bib12">Cham et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Dong et al., 2020</xref>). Correspondingly, we show that the immune environment of the <italic>Pten<sup>fl/fl</sup></italic> mouse prostate is highly enriched for pro-tumorigenic immune cells, specifically immunosuppressive myeloid cells and exhausted CD8<sup>+</sup> T cells. We carefully delineated cell-cell signaling patterns and found that epithelial cells, fibroblasts, and macrophages contribute to immune recruitment. Since M2 and tumor-associated macrophages most significantly contribute to recruitment of other immune cells, macrophages are likely activated and recruited first during tumorigenesis, and subsequently emit chemokines and other ligands that help attract and exhaust CD8<sup>+</sup> T cells as well as pro-tumorigenic MDSCs. Interestingly, specific macrophage subtypes seem differentially responsible for distinct recruitment patterns: M2 macrophages express very high levels of MDSC-associated chemokines, while TAMs recruit CD8<sup>+</sup> T cells via high expression of <italic>Cxcl16</italic> and <italic>Cd86</italic>. Given these results, interrupting the recruitment of tumor-associated macrophages may be a valid strategy for depleting pro-tumorigenic immune populations and overcoming immunotherapy resistance in prostate cancer. In vitro studies utilizing co-cultures of epithelial and immune cells will be required to validate these in silico results and confirm whether the epithelia-macrophage signaling axis is an appropriate therapeutic target.</p><p>Androgen deprivation in the <italic>Pten<sup>fl/fl</sup></italic> mouse leads to a decrease in macrophage and CD8<sup>+</sup> T cell abundance, likely due to ablation of fibroblast-mediated chemokine signaling. Androgen signaling is active in tissue-resident macrophages and can induce pro-tumorigenic behaviors including increased migration and proliferation in prostate cancer cells (<xref ref-type="bibr" rid="bib16">Cioni et al., 2020</xref>). In addition, AR can promote <italic>Ccr2</italic> expression and facilitate macrophage activity and recruitment (<xref ref-type="bibr" rid="bib48">Lai et al., 2009</xref>). This corresponds well to our finding that fibroblast-mediated signaling towards <italic>Ccr2</italic> contributes to macrophage recruitment and is interrupted upon castration, and suggests that androgen deprivation decreases macrophage abundance in the prostate tumor environment. Conversely, castration increased <italic>Tnf</italic> signaling from myeloid cells to epithelial cells and fibroblasts. TNF signaling has been described as pro-tumorigenic in AR-low prostate cancer (<xref ref-type="bibr" rid="bib58">Mizokami et al., 2000</xref>; <xref ref-type="bibr" rid="bib67">Sha et al., 2015</xref>), and we confirmed that TNF activity was inversely associated with AR activity in human patients. This paradigm supports the role of macrophages and neutrophils in maintaining a favorable tumor environment even in the context of androgen loss and suggests a mechanistic relationship between castration and pro-tumorigenic immune signaling.</p><p>Finally, we tested the hypothesis that high translation rates were important to maintain AR-low prostate cancer heterogeneity using the <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mouse model. We discovered that 4ebp1<sup>M</sup> induction severely depleted both basal and intermediate cells. Interestingly, hyper-proliferative basal cells were preferentially depleted, leading to a decrease in overall basal cell proliferation. In addition, <italic>Egfr</italic> and <italic>Tnf</italic> signaling were decreased in the tumor microenvironment. We conclude that high translation rates are essential to maintain tumor heterogeneity in AR-low prostate cancer and may play a role in pro-tumorigenic cell-cell communication pathways. Based on these findings, we speculate that translation inhibitors may represent a therapeutic modality to decrease tumor heterogeneity, and that additional studies may uncover further druggable targets. Overall, our work highlights multiple epithelial and immune cell types crucial to prostate cancer initiation and progression and elucidates interactions between specific cell populations that may facilitate castration resistance. Lastly, this work aims to provide a broad, searchable resource to the cancer research community. To this end, we have developed a publicly accessible and interactive website (available at <ext-link ext-link-type="uri" xlink:href="https://atlas.fredhutch.org/hsieh-prostate/">https://atlas.fredhutch.org/hsieh-prostate/</ext-link>) that allows for cell- and gene-specific queries through all 50,780 cells analyzed in this study (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p><italic>PB-Cre4</italic> mice which express a <italic>Cre</italic> recombinase transgene under the control of the rat <italic>Pbsn</italic> (probasin) promoter in the prostate epithelium were obtained from the Mouse Models of Human Cancer Consortium (now Jax #026662). <italic>Pten<sup>fl/fl</sup></italic> (Jax #006440) and <italic>Rosa-LSL-rtTA</italic> (Jax #005670) mice were obtained from the Jackson Laboratory. <italic>TetO-</italic>4ebp1<sup>M</sup> mice which express an inducible mutant <italic>Eif4ebp1</italic> transgene were generated as previously described (<xref ref-type="bibr" rid="bib32">Hsieh et al., 2010</xref>). All mice were maintained in the C57BL/6 background under specific pathogen–free conditions, and experiments conformed to the guidelines as approved by the Institutional Animal Care and Use Committee of Fred Hutchinson Cancer Research Center.</p></sec><sec id="s4-2"><title>Surgical castration and activation of the 4EBP1<sup>M</sup> transgene</title><p>Surgical castrations were performed in 4- to 5-month-old mice under isoflurane anesthesia. Postoperatively, mice were monitored daily for 5 days. To activate the 4EBP1<sup>M</sup> transgene, doxycycline (Sigma-Aldrich) was administered in the drinking water at 2 g/liter immediately after castration, and euthanasia was performed 8 weeks after castration.</p></sec><sec id="s4-3"><title>Tissue dissociation for single-cell RNA sequencing</title><p>Ventral prostate lobes from C57BL/6 J WT, <italic>Pten<sup>fl/fl</sup>, Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mice were dissected, washed with chilled 1 X PBS, and then minced with a scalpel into small pieces (~1 mm) in a petri dish. Paired lobes from a single mouse were collected and dissociated into one sample for scRNA-seq. The tissue was digested with DMEM/F12/Collagenase/Hyaluronidase/FBS (StemCell technologies, Vancouver, Canada) for 1 hr at 37 °C on a slowly shaking/rotating platform. The tissue was further digested in 0.25% Trypsin-EDTA (Invitrogen, Carlsbad, CA) on ice for 30 minutes, and followed by suspension in Dispase (Invitrogen, Carlsbad, CA, 5 mg/mL) and DNase I (Roche Applied Science, Indianapolis, IN, 1 mg/mL). Any cell clumps were dissociated by gently pipetting up and down. The dissociated cells were then passed through 70 μm cell strainers (BD Biosciences, San Jose, CA) to achieve single cell suspension. The suspension was resuspended with 3 ml PBS (Life Technologies) with 2% fetal calf serum (FCS) (Gemini Bioproducts, West Sacramento, CA) and immediately placed on ice. Viable cells were counted by Vi-Cell XR Cell Viability Analyzer (Beckman Coulter, Brea, CA) and then diluted accordingly to reach the targeted cell concentration.</p></sec><sec id="s4-4"><title>Single-cell RNA sequencing library preparation</title><p>3’ single-cell RNA libraries were generated according to the protocol outlined in Single Cell 3’ Reagent Kits v2 User Guide 10 X Genomics. Briefly, cells and reverse transcription reagents were partitioned into oil-based Gel Beads in Emulsion (GEMs), with each GEM containing a unique 10 x barcode. Cells were then lysed and underwent reverse transcription resulting in barcoded cDNA. The cDNA was then collected and amplified prior to undergoing library construction in which P5, P7, and a unique sample index were added.</p><p>At least two mouse prostates were prepared and sequenced for each condition in order to obtain &gt;10,000 cells/condition, resulting in n=3 for WT mice, n=2 for <italic>Pten<sup>fl/fl</sup></italic> mice, n=3 for <italic>Pten<sup>fl/fl</sup></italic> mice, and n=2 for <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mice. Individual mouse prostates were considered biological replicates. The 10 libraries generated in this manner were pooled and sequencing was performed on an Illumina NovaSeq 6000 using the v1.5 S1-100 flow cell and reagent kit. Sequencing configuration was paired-end 26x8 × 96 and Illumina RTA version v3.3.5 was used. This generated a median of 58.7 million reads/sample with a median 54.60% saturation, median 90.70% Q30 fraction, 13,746 average reads/cell, and 6.2 reads/UMI.</p></sec><sec id="s4-5"><title>Alignment and filtering of reads</title><p>Two transgene transcripts (<italic>Cre</italic>, <italic>rtTA-eGFP</italic>) were added to the mm10 transcriptome to detect transgenes expressed in the <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> mice. Kallisto v0.45.1 (<xref ref-type="bibr" rid="bib10">Bray et al., 2016</xref>) was used to demultiplex all samples into FASTQ files and align reads to the modified mm10 transcriptome. DropletUtils package (<xref ref-type="bibr" rid="bib55">Lun et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Griffiths et al., 2018</xref>) was used to filter out empty or duplexed cell droplets. Cells with fewer than 200 or greater than 5000 detected genes, fewer than 500 or greater than 25,000 detected UMIs and cells with &gt;15% mitochondrial reads were filtered from subsequent analysis.</p></sec><sec id="s4-6"><title>PCA, UMAP, and clustering</title><p>R package Seurat v4.0.4 (<ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/">https://satijalab.org/seurat/</ext-link>) was used to construct a Principal Component Analysis (PCA) for the entire dataset using the 2000 most variable genes as features. The Uniform Manifold Approximation and Projection (UMAP) dimension reduction technique was used for visualization and the R function ‘FindClusters()’ with resolution = 0.2 was used to generate 43 clusters.</p></sec><sec id="s4-7"><title>Cell type identification</title><p>The SingleR package v1.6.1 was used to assign initial cell type identities to each cluster. These IDs were verified and refined using expression patterns of published biomarkers. For epithelial cells, cell subtypes (basal, intermediate, differentiated) were assigned using published gene signatures from other single-cell RNA sequencing projects. For immune cells, broad cell types (T cells, macrophages) were divided into activation states via known biomarkers (e.g. <italic>Cd8a</italic> for CD8 T cells and <italic>Mrc1</italic> for M2-activated macrophages). Stromal cell types were also determined via biomarkers.</p></sec><sec id="s4-8"><title>Relative cell abundance</title><p>To compare the abundance of specific cell populations while controlling for sample library size, the percentage composition of each sample was calculated by cell type. Statistical significance was generated via a negative binomial regression test to determine whether a given cell type was over- or under-represented between conditions.</p></sec><sec id="s4-9"><title>Gene signature enrichment</title><p>The GSVA package v1.40.1 (<xref ref-type="bibr" rid="bib30">Hänzelmann et al., 2013</xref>) was used to generate composite scores for gene signatures such as a 20-gene AR activity signature or the 30-gene CCP proliferation signature. Due to the sparse nature of single-cell transcriptomes, the data was pseudo-bulked by sample and cell type to generate more robust analyses. Statistical analysis was performed via permutation test with 10,000 permutations.</p></sec><sec id="s4-10"><title>Differential expression and gene set enrichment analysis</title><p>Differential gene expression was computed using Seurat functions with a threshold log2 fold-change &gt;0.25 or&lt;–0.25 and FDR &lt;0.05. Upregulated and downregulated genes were further filtered by setting a log2 fold-change threshold = log2(1.25) = ~0.32. Gene names were converted from mouse to human via the biomaRt package (<xref ref-type="bibr" rid="bib21">Durinck et al., 2009</xref>) and GSEA was performed using the MsigDB database with the C2, C5, C6, C7, Hallmark, KEGG, BioCarta, and Reactome gene sets. Resulting enriched pathways were filtered via a threshold of FDR &lt;0.05.</p></sec><sec id="s4-11"><title>Trajectory, RNA velocity, and pseudotime</title><p>Monocle3 (<xref ref-type="bibr" rid="bib11">Cao et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Qiu et al., 2017</xref>; <xref ref-type="bibr" rid="bib74">Trapnell et al., 2014</xref>) and velocyto (<xref ref-type="bibr" rid="bib49">La Manno et al., 2018</xref>) were used to draw trajectory paths and RNA velocity maps, respectively, through the epithelial compartment of the <italic>Pten<sup>fl/fl</sup></italic> intact mice. Palantir (<xref ref-type="bibr" rid="bib66">Setty et al., 2019</xref>) was used to delineate gene expression dynamics across pseudotime in basal and intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> intact mice.</p></sec><sec id="s4-12"><title>Ligand-receptor interactions</title><p>Ligand-receptor interactions between cell types were determined via the CellphoneDB package v2.0.0 (<xref ref-type="bibr" rid="bib22">Efremova et al., 2020</xref>). Only interaction with p-value &lt;0.05 were included in the final analysis.</p></sec><sec id="s4-13"><title>Cell cycle assignment</title><p>Cell cycle phases for single cells were determined using the Seurat cell cycle function, which includes gene lists denoting the G2M and S phases. Gene names were converted from human to mouse using the biomaRt package to match our data, then the CellCycleScoring function was used to assign each cell either S, G2M, or G1 phase. Chi-squared test was used to determine whether the proportions of G1 cells were significantly different between clusters or conditions.</p></sec><sec id="s4-14"><title>Human gene signature of ADT resistance and correlation to mouse data</title><p>Tumor samples were laser capture microdissected from prostate cancer biopsies prior to undergoing six months of neoadjuvant androgen deprivation therapy plus enzalutamide and ranked based on volume of residual tumor in each patient, as previously described (<xref ref-type="bibr" rid="bib38">Karzai et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Wilkinson et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Ku et al., 2021</xref>). Separately, differentially expressed genes (DEGs) derived from the PTEN null intact and castrate basal or intermediate cells were converted from mouse to human gene symbols using getLDS function from the biomaRt package v2.48.3 for R/Bioconductor (<xref ref-type="bibr" rid="bib21">Durinck et al., 2009</xref>). Gene set enrichment analysis (GSEA) was performed on the basal vs. intermediate DEGs set against the top 50 genes associated with treatment resistance, and the top five leading edge genes from GSEA were used to stratify samples. Survival analysis was performed using the <italic>survival</italic> package in R on the TCGA prostate adenocarcinoma (<xref ref-type="bibr" rid="bib60">Network, 2015</xref>) (n=490) and MSKCC (<xref ref-type="bibr" rid="bib73">Taylor et al., 2010</xref>) (n=140) datasets. A cancer sample was considered “altered” if the expression of at least one of the five leading edge genes was greater than the 80th percentile for the entire cohort (TCGA or MSKCC, respectively).</p></sec><sec id="s4-15"><title>Integration of single-cell data from human patients</title><p>Sequencing data from human primary tumor samples was contributed by Dr. Franklin Huang. Data from human metastatic tumor samples was obtained from the GEO repository of <xref ref-type="bibr" rid="bib20">Dong et al., 2020</xref>. All primary and metastatic samples were processed individually via the standard Seurat workflow. The primary sample object was filtered to only retain confirmed malignant cells. All objects were integrated into a Seurat object using a standard workflow (<ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/articles/integration_introduction.html">available here</ext-link>) and visualized via the UMAP dimension reduction method. The AddModuleScore function was used to compute the 5-gene signature score for every cell and was visualized via the FeaturePlot function.</p></sec><sec id="s4-16"><title>Orthogonal mouse model</title><p>Data from individual <italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup></italic> (PR) and <italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup>/Nmyc<sup>+</sup></italic> (PRN) mice were aggregated using the cellranger aggr pipeline and visualized using Loupe Cell Browser. Quantification of gene expression signatures was performed using the sum of log 2 -transformed normalized UMI counts across all genes in the signature. Cells were stratified into equal-sized tertiles (low, intermediate, high) based on the maximum value of the signature score. Cells with no detectable UMI counts of any signature genes were assigned to the zero category.</p></sec><sec id="s4-17"><title>TCGA analysis of TNF activity</title><p>The Cancer Genome Atlas (TCGA) PRAD cohort containing 493 primary prostate tumor samples with RNA-seq expression values was utilized for analysis of signature scores. We used the RSEM values hosted by the cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>, study: prad_tcga_pan_can_atlas_2018.) Single sample enrichment scores were calculated using GSVA (<xref ref-type="bibr" rid="bib30">Hänzelmann et al., 2013</xref>) with default parameters using genome-wide log2 RSEM values as input. The pathways used were from MSigDBv7.4 (HALLMARK_TNFA_SIGNALING_VIA_NFKB) and the 10-gene androgen-regulated (AR) signature from <xref ref-type="bibr" rid="bib7">Bluemn et al., 2017</xref>. In analyses restricted to samples with PTEN biallelic loss, 94 samples were used which had either 2 copy loss or 1 copy loss and a non-synonymous mutation annotated as a putative driver mutation in cBioPortal. Pearson’s correlation coefficient was used to study the relationships between signature scores shown in scatterplots using the cor.test function in R.</p></sec><sec id="s4-18"><title>Data and code availability</title><p>The single-cell RNA sequencing data files are available on the GEO database at GSE171336 and can be accessed using token: ijmfokccrhepvub. The code used to process and analyze the data is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/sonali-bioc/GermanosProstatescRNASeq/">https://github.com/sonali-bioc/GermanosProstatescRNASeq/</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e9938d1f7015d22d13d61d7432906203a30fadea;origin=https://github.com/sonali-bioc/GermanosProstatescRNASeq;visit=swh:1:snp:77f3c5d2786f438b5fe939fe7e7222f98929bdb4;anchor=swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448">swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448</ext-link>; <xref ref-type="bibr" rid="bib5">Arora, 2022</xref>). All other data associated with this study are present in supplementary materials and tables.</p></sec><sec id="s4-19"><title>Interactive website</title><p>The web-based data Atlas was developed utilizing open-source technologies, including React for the application framework, Material UI for interface components, and Apache EChart for visualizations. All data were extracted from Seurat HDF5 files into web-optimized CSV, Arrow, and Binary files. All site data and assets are stored in Amazon S3 and served through Amazon CloudFront, a global content delivery network (CDN) service built for high-speed, low-latency performance and security. The site is hosted at <ext-link ext-link-type="uri" xlink:href="https://atlas.fredhutch.org/hsieh-prostate/">https://atlas.fredhutch.org/hsieh-prostate/</ext-link>.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Methodology, Software, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Visualization</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Visualization</p></fn><fn fn-type="con" id="con7"><p>Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Validation, Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Methodology, Visualization</p></fn><fn fn-type="con" id="con10"><p>Validation, Methodology, Software</p></fn><fn fn-type="con" id="con11"><p>Data curation, Supervision, Visualization</p></fn><fn fn-type="con" id="con12"><p>Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Methodology, Supervision</p></fn><fn fn-type="con" id="con14"><p>Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Methodology, Software</p></fn><fn fn-type="con" id="con16"><p>Methodology, Supervision</p></fn><fn fn-type="con" id="con17"><p>Methodology, Validation</p></fn><fn fn-type="con" id="con18"><p>Formal analysis, Validation</p></fn><fn fn-type="con" id="con19"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con20"><p>Data curation, Formal analysis, Supervision</p></fn><fn fn-type="con" id="con21"><p>Formal analysis, Methodology, Software, Visualization</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Funding acquisition, Supervision, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice were maintained in the C57BL/6 background under specific pathogen-free conditions, and experiments conformed to the guidelines as approved by the Institutional Animal Care and Use Committee (#50870) of Fred Hutchinson Cancer Research Center (FHCRC).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Quality control metrics and <xref ref-type="fig" rid="fig1">Figure 1</xref> supplementary information.</title><p>(A) Quality control measures for each mouse replicate. (B) Breakdown of cell ID numbers and relative abundance (%) per mouse condition. (C) Breakdown of cell ID numbers and relative abundance (%) per mouse replicate. (D) Genes upregulated in <italic>Pten<sup>fl/fl</sup></italic> compared to WT mice for each epithelial subtype. Thresholds set at avg_log2FC &gt;0.25 and FDR &lt;0.05. (E) Breakdown of cell cycle phase assignment for every cell ID in WT and <italic>Pten<sup>fl/fl</sup></italic> mice. (F) Differentially expressed genes between hyper-proliferative and hypo-proliferative basal cells in <italic>Pten<sup>fl/fl</sup></italic> mice. Thresholds set at avg_log2FC &gt;0.25 and FDR &lt;0.05. Positive avg_log2FC values indicate upregulation in hypo-proliferative basal cells.</p></caption><media xlink:href="elife-79076-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>CellphoneDB cell-cell interaction data in <italic>Pten<sup>fl/fl</sup></italic> mice (see <xref ref-type="fig" rid="fig2">Figure 2</xref>).</title><p>The first gene in the “pair” column is expressed in the first cell ID in the “clusters” column and the second gene is expressed in the second cell ID.</p></caption><media xlink:href="elife-79076-supp2-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Differentially expressed genes in <italic>Pten<sup>fl/fl</sup></italic> and <italic>Pten<sup>fl/fl</sup></italic> cx intermediate cells.</title><p>6-way comparison between clusters 0–5 (see <xref ref-type="fig" rid="fig3">Figure 3E</xref>). Each sheet shows significantly up- or down-regulated genes for one cluster relative to all others. Thresholds set at avg_log2FC &gt;0.25 and FDR &lt;0.05.</p></caption><media xlink:href="elife-79076-supp3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>CellphoneDB cell-cell interaction data in <italic>Pten<sup>fl/fl</sup></italic> cx mice (see <xref ref-type="fig" rid="fig5">Figure 5</xref>).</title><p>The first gene in the “pair” column is expressed in the first cell ID in the “clusters” column and the second gene is expressed in the second cell ID.</p></caption><media xlink:href="elife-79076-supp4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Differentially expressed genes and CellphoneDB cell-cell interaction data in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice (see <xref ref-type="fig" rid="fig6">Figure 6</xref>).</title><p>(A) Genes upregulated in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx compared to <italic>Pten<sup>fl/fl</sup></italic> cx mice for each epithelial subtype. Thresholds set at avg_log2FC &gt;0.25 and FDR &lt;0.05. (B) Genes upregulated in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx compared to <italic>Pten<sup>fl/fl</sup></italic> cx mice for each epithelial subtype, filtered for cells expressing the <italic>rtTA-eGFP</italic> transgene. Thresholds set at avg_log2FC &gt;0.25 and FDR &lt;0.05. (C) CellphoneDB cell-cell interaction data in <italic>Pten<sup>fl/fl</sup>;</italic>4ebp1<sup>M</sup> cx mice (see <xref ref-type="fig" rid="fig6">Figure 6E–H</xref>). The first gene in the “pair” column is expressed in the first cell ID in the “clusters” column and the second gene is expressed in the second cell ID.</p></caption><media xlink:href="elife-79076-supp5-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79076-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in GEO under accession code GSE17133. All code used for this study is available on Github at <ext-link ext-link-type="uri" xlink:href="https://github.com/sonali-bioc/GermanosProstatescRNASeq/">https://github.com/sonali-bioc/GermanosProstatescRNASeq/</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e9938d1f7015d22d13d61d7432906203a30fadea;origin=https://github.com/sonali-bioc/GermanosProstatescRNASeq;visit=swh:1:snp:77f3c5d2786f438b5fe939fe7e7222f98929bdb4;anchor=swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448">swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Germanos</surname><given-names>A</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Hsieh</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Defining Cellular Population Dynamics in Advanced Prostate Cancer using Single-cell RNA Sequencing</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171336">GSE171336</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><collab>Network TCGAR</collab></person-group><year iso-8601-date="2015">2015</year><data-title>TCGA</data-title><source>GDC Data Portal</source><pub-id pub-id-type="accession" xlink:href="https://portal.gdc.cancer.gov/">TCGA</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Carver</surname><given-names>BS</given-names></name><name><surname>Arora Vivek</surname><given-names>K</given-names></name><name><surname>Major John</surname><given-names>E</given-names></name><name><surname>Socci Nicholas</surname><given-names>D</given-names></name><name><surname>Lash Alex</surname><given-names>E</given-names></name><name><surname>Eastham James</surname><given-names>A</given-names></name><name><surname>Reuter Victor</surname><given-names>E</given-names></name><name><surname>Scardino Peter</surname><given-names>T</given-names></name><name><surname>Sawyers Charles</surname><given-names>L</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Poorvi</surname><given-names>K</given-names></name><name><surname>Ethan</surname><given-names>C</given-names></name><name><surname>Boris</surname><given-names>R</given-names></name><name><surname>Yevgeniy</surname><given-names>A</given-names></name><name><surname>Nicholas</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Igor</surname><given-names>D</given-names></name><name><surname>Manda</surname><given-names>W</given-names></name><name><surname>Adriana</surname><given-names>H</given-names></name><name><surname>Howard</surname><given-names>S</given-names></name><name><surname>Chris</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>Prostate Adenocarcinoma (MSK, Cancer Cell 2010)</data-title><source>cBioPortal</source><pub-id pub-id-type="accession" xlink:href="http://www.cbioportal.org/study/summary?id=prad_mskcc">prad_mskcc</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Jinming</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>HH</given-names></name><name><surname>Chua</surname><given-names>CW</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137829">GSE137829</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Weinstein</surname><given-names>HNW</given-names></name><name><surname>Allegakoen</surname><given-names>P</given-names></name><name><surname>Wadsworth</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Castro</surname><given-names>EA</given-names></name><name><surname>Stohr</surname><given-names>BA</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Cooperberg</surname><given-names>MR</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176031">GSE176031</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>NJ</given-names></name><name><surname>Bagadion</surname><given-names>AM</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Conteduca</surname><given-names>V</given-names></name><name><surname>Emmenis</surname><given-names>LV</given-names></name><name><surname>Arceci</surname><given-names>E</given-names></name><name><surname>Pakula</surname><given-names>H</given-names></name><name><surname>Carelli</surname><given-names>R</given-names></name><name><surname>Khani</surname><given-names>F</given-names></name><name><surname>Bakht</surname><given-names>M</given-names></name><name><surname>Sigouros</surname><given-names>M</given-names></name><name><surname>Bareja</surname><given-names>R</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Tagawa</surname><given-names>S</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>B</given-names></name><name><surname>Rickman</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151426">GSE151426</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to the patients who participated in this study and their families. We thank members of the ACH laboratory for helpful advice and discussions. We thank the Seattle RNA Metabolism group for critical discussion of the work. We thank L Xin for sharing RNA-seq data and critical reading of the manuscript. This work was supported by NIH award R37 CA230617, R01 GM135362, the Pacific Northwest Prostate Cancer SPORE DRP (P50 CA097186), Burroughs Welcome Fund, Career Award for Medicine Scientists (1012314.02), and grants from the Emerson Collective (691630), and the Robert J Kleberg Jr. and Helen C Kleberg Foundation to ACH. AAG received funding through an NIH T32 grant (T32 CA080416) and ETG reviewed funding from the DoD BCRP Breakthrough Fellowship Award (W81XWH-19-1-0076). This research was also supported by P01 CA163227 and R01 CA234715 to PSN, the Prostate Cancer Foundation, the Genomics and Bioinformatics Shared Resource of the Fred Hutch/University of Washington Cancer Consortium (P30 CA015704) and the Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10 OD028685.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allott</surname><given-names>EH</given-names></name><name><surname>Masko</surname><given-names>EM</given-names></name><name><surname>Freedland</surname><given-names>AR</given-names></name><name><surname>Macias</surname><given-names>E</given-names></name><name><surname>Pelton</surname><given-names>K</given-names></name><name><surname>Solomon</surname><given-names>KR</given-names></name><name><surname>Mostaghel</surname><given-names>EA</given-names></name><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Pizzo</surname><given-names>SV</given-names></name><name><surname>Freeman</surname><given-names>MR</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer</article-title><source>Prostate Cancer and Prostatic Diseases</source><volume>21</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/s41391-018-0045-x</pub-id><pub-id pub-id-type="pmid">29795142</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshetaiwi</surname><given-names>H</given-names></name><name><surname>Pervolarakis</surname><given-names>N</given-names></name><name><surname>McIntyre</surname><given-names>LL</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>Q</given-names></name><name><surname>Rath</surname><given-names>JA</given-names></name><name><surname>Nee</surname><given-names>K</given-names></name><name><surname>Hernandez</surname><given-names>G</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Torosian</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>C</given-names></name><name><surname>Kessenbrock</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eaay6017</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aay6017</pub-id><pub-id pub-id-type="pmid">32086381</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoch</surname><given-names>MP</given-names></name><name><surname>Wrobel</surname><given-names>M</given-names></name><name><surname>Gillard</surname><given-names>B</given-names></name><name><surname>Kuropatwinski</surname><given-names>KK</given-names></name><name><surname>Toshkov</surname><given-names>I</given-names></name><name><surname>Gleiberman</surname><given-names>AS</given-names></name><name><surname>Karasik</surname><given-names>E</given-names></name><name><surname>Moser</surname><given-names>MT</given-names></name><name><surname>Foster</surname><given-names>BA</given-names></name><name><surname>Andrianova</surname><given-names>EL</given-names></name><name><surname>Chernova</surname><given-names>OV</given-names></name><name><surname>Gudkov</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer</article-title><source>Oncotarget</source><volume>11</volume><fpage>1373</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27550</pub-id><pub-id pub-id-type="pmid">32341756</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D</given-names></name><name><surname>Looney</surname><given-names>AP</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>E</given-names></name><name><surname>Fong</surname><given-names>V</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Chak</surname><given-names>S</given-names></name><name><surname>Naikawadi</surname><given-names>RP</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name><name><surname>Abate</surname><given-names>AR</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><name><surname>Bhattacharya</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reference-Based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title><source>Nature Immunology</source><volume>20</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0276-y</pub-id><pub-id pub-id-type="pmid">30643263</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>GermanosProstatescRNASeq</data-title><version designator="swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448">swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e9938d1f7015d22d13d61d7432906203a30fadea;origin=https://github.com/sonali-bioc/GermanosProstatescRNASeq;visit=swh:1:snp:77f3c5d2786f438b5fe939fe7e7222f98929bdb4;anchor=swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448">https://archive.softwareheritage.org/swh:1:dir:e9938d1f7015d22d13d61d7432906203a30fadea;origin=https://github.com/sonali-bioc/GermanosProstatescRNASeq;visit=swh:1:snp:77f3c5d2786f438b5fe939fe7e7222f98929bdb4;anchor=swh:1:rev:5a376d7b77d034e9bd09ce4787337ee33fda8448</ext-link></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becerra-Diaz</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Heller</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>1698</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01698</pub-id><pub-id pub-id-type="pmid">32849595</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluemn</surname><given-names>EG</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Lucas</surname><given-names>JM</given-names></name><name><surname>Coleman</surname><given-names>RT</given-names></name><name><surname>Hernandez-Lopez</surname><given-names>S</given-names></name><name><surname>Tharakan</surname><given-names>R</given-names></name><name><surname>Bianchi-Frias</surname><given-names>D</given-names></name><name><surname>Dumpit</surname><given-names>RF</given-names></name><name><surname>Kaipainen</surname><given-names>A</given-names></name><name><surname>Corella</surname><given-names>AN</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Nyquist</surname><given-names>MD</given-names></name><name><surname>Mostaghel</surname><given-names>E</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Pienta</surname><given-names>K</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name><name><surname>Schweizer</surname><given-names>M</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Wise</surname><given-names>D</given-names></name><name><surname>Rennie</surname><given-names>PS</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling</article-title><source>Cancer Cell</source><volume>32</volume><fpage>474</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.09.003</pub-id><pub-id pub-id-type="pmid">29017058</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boesteanu</surname><given-names>AC</given-names></name><name><surname>Katsikis</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Memory T cells need CD28 costimulation to remember</article-title><source>Seminars in Immunology</source><volume>21</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2009.02.005</pub-id><pub-id pub-id-type="pmid">19268606</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>NJ</given-names></name><name><surname>Bagadion</surname><given-names>AM</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Conteduca</surname><given-names>V</given-names></name><name><surname>Emmenis</surname><given-names>LV</given-names></name><name><surname>Arceci</surname><given-names>E</given-names></name><name><surname>Pakula</surname><given-names>H</given-names></name><name><surname>Carelli</surname><given-names>R</given-names></name><name><surname>Khani</surname><given-names>F</given-names></name><name><surname>Bakht</surname><given-names>M</given-names></name><name><surname>Sigouros</surname><given-names>M</given-names></name><name><surname>Bareja</surname><given-names>R</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Tagawa</surname><given-names>S</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>B</given-names></name><name><surname>Rickman</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer</article-title><source>Nat Commun</source><volume>12</volume><elocation-id>3372</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23780-y</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Spielmann</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ibrahim</surname><given-names>DM</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name><name><surname>Christiansen</surname><given-names>L</given-names></name><name><surname>Steemers</surname><given-names>FJ</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The single-cell transcriptional landscape of mammalian organogenesis</article-title><source>Nature</source><volume>566</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0969-x</pub-id><pub-id pub-id-type="pmid">30787437</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cham</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kwek</surname><given-names>S</given-names></name><name><surname>Paciorek</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Fong</surname><given-names>G</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies</article-title><source>Journal for Immunotherapy of Cancer</source><volume>8</volume><elocation-id>e000368</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2019-000368</pub-id><pub-id pub-id-type="pmid">32376721</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanmee</surname><given-names>T</given-names></name><name><surname>Ontong</surname><given-names>P</given-names></name><name><surname>Konno</surname><given-names>K</given-names></name><name><surname>Itano</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tumor-Associated macrophages as major players in the tumor microenvironment</article-title><source>Cancers</source><volume>6</volume><fpage>1670</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.3390/cancers6031670</pub-id><pub-id pub-id-type="pmid">25125485</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name><name><surname>Xin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation</article-title><source>Cancer Cell</source><volume>21</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.01.005</pub-id><pub-id pub-id-type="pmid">22340597</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Minkina</surname><given-names>A</given-names></name><name><surname>Chardon</surname><given-names>FM</given-names></name><name><surname>Suiter</surname><given-names>CC</given-names></name><name><surname>Regalado</surname><given-names>SG</given-names></name><name><surname>Domcke</surname><given-names>S</given-names></name><name><surname>Hamazaki</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Daza</surname><given-names>RM</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A time-resolved, multi-symbol molecular recorder via sequential genome editing</article-title><source>Nature</source><volume>608</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04922-8</pub-id><pub-id pub-id-type="pmid">35794474</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cioni</surname><given-names>B</given-names></name><name><surname>Zaalberg</surname><given-names>A</given-names></name><name><surname>van Beijnum</surname><given-names>JR</given-names></name><name><surname>Melis</surname><given-names>MHM</given-names></name><name><surname>van Burgsteden</surname><given-names>J</given-names></name><name><surname>Muraro</surname><given-names>MJ</given-names></name><name><surname>Hooijberg</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>D</given-names></name><name><surname>Hofland</surname><given-names>I</given-names></name><name><surname>Lubeck</surname><given-names>Y</given-names></name><name><surname>de Jong</surname><given-names>J</given-names></name><name><surname>Sanders</surname><given-names>J</given-names></name><name><surname>Vivié</surname><given-names>J</given-names></name><name><surname>van der Poel</surname><given-names>HG</given-names></name><name><surname>de Boer</surname><given-names>JP</given-names></name><name><surname>Griffioen</surname><given-names>AW</given-names></name><name><surname>Zwart</surname><given-names>W</given-names></name><name><surname>Bergman</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4498</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18313-y</pub-id><pub-id pub-id-type="pmid">32908142</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>L</given-names></name><name><surname>Cambuli</surname><given-names>F</given-names></name><name><surname>Aparicio</surname><given-names>L</given-names></name><name><surname>Shibata</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>Xuan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors</article-title><source>eLife</source><volume>9</volume><elocation-id>e59465</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59465</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Swanson</surname><given-names>GP</given-names></name><name><surname>Fisher</surname><given-names>G</given-names></name><name><surname>Brothman</surname><given-names>AR</given-names></name><name><surname>Berney</surname><given-names>DM</given-names></name><name><surname>Reid</surname><given-names>JE</given-names></name><name><surname>Mesher</surname><given-names>D</given-names></name><name><surname>Speights</surname><given-names>VO</given-names></name><name><surname>Stankiewicz</surname><given-names>E</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Møller</surname><given-names>H</given-names></name><name><surname>Scardino</surname><given-names>P</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Younus</surname><given-names>A</given-names></name><name><surname>Flake</surname><given-names>DD</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Gutin</surname><given-names>A</given-names></name><name><surname>Lanchbury</surname><given-names>JS</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><collab>Transatlantic Prostate Group</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study</article-title><source>The Lancet. Oncology</source><volume>12</volume><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70295-3</pub-id><pub-id pub-id-type="pmid">21310658</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>C-J</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ho</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>SR</given-names></name><name><surname>Labrot</surname><given-names>ES</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Lis</surname><given-names>R</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Hiller</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Stegh</surname><given-names>AH</given-names></name><name><surname>Scott</surname><given-names>KL</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Mucci</surname><given-names>L</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression</article-title><source>Nature</source><volume>470</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/nature09677</pub-id><pub-id pub-id-type="pmid">21289624</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Jinming</surname><given-names>W</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>HH</given-names></name><name><surname>Chua</surname><given-names>CW</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer</article-title><source>Commun Biology</source><volume>3</volume><elocation-id>778</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-01476-1</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomart</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.97</pub-id><pub-id pub-id-type="pmid">19617889</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>M</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes</article-title><source>Nature Protocols</source><volume>15</volume><fpage>1484</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-0292-x</pub-id><pub-id pub-id-type="pmid">32103204</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>AJ</given-names></name><name><surname>Ruscetti</surname><given-names>M</given-names></name><name><surname>Arenzana</surname><given-names>TL</given-names></name><name><surname>Tran</surname><given-names>LM</given-names></name><name><surname>Bianci-Frias</surname><given-names>D</given-names></name><name><surname>Sybert</surname><given-names>E</given-names></name><name><surname>Priceman</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Smale</surname><given-names>ST</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>2017</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1128/MCB.00090-14</pub-id><pub-id pub-id-type="pmid">24662052</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gmünder</surname><given-names>H</given-names></name><name><surname>Lesslauer</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses</article-title><source>European Journal of Biochemistry</source><volume>142</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1984.tb08263.x</pub-id><pub-id pub-id-type="pmid">6235110</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>AS</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Garraway</surname><given-names>IP</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Identification of a cell of origin for human prostate cancer</article-title><source>Science</source><volume>329</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1126/science.1189992</pub-id><pub-id pub-id-type="pmid">20671189</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>JA</given-names></name><name><surname>Richard</surname><given-names>AC</given-names></name><name><surname>Bach</surname><given-names>K</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Detection and removal of barcode swapping in single-cell RNA-seq data</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2667</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05083-x</pub-id><pub-id pub-id-type="pmid">29991676</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griss</surname><given-names>J</given-names></name><name><surname>Viteri</surname><given-names>G</given-names></name><name><surname>Sidiropoulos</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Fabregat</surname><given-names>A</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ReactomeGSA - efficient multi-omics comparative pathway analysis</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>19</volume><fpage>2115</fpage><lpage>2125</lpage><pub-id pub-id-type="doi">10.1074/mcp.TIR120.002155</pub-id><pub-id pub-id-type="pmid">32907876</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guérin</surname><given-names>O</given-names></name><name><surname>Fischel</surname><given-names>JL</given-names></name><name><surname>Ferrero</surname><given-names>JM</given-names></name><name><surname>Bozec</surname><given-names>A</given-names></name><name><surname>Milano</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>EGFR targeting in hormone-refractory prostate cancer</article-title><source>Current Appraisal and Prospects for Treatment. Pharm</source><volume>3</volume><fpage>2238</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.3390/ph3072238</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Aji</surname><given-names>R</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips</article-title><source>Nature Genetics</source><volume>52</volume><fpage>908</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0642-1</pub-id><pub-id pub-id-type="pmid">32807988</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hänzelmann</surname><given-names>S</given-names></name><name><surname>Castelo</surname><given-names>R</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title><source>Bmc Bioinformatics</source><volume>14</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-7</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>KN</given-names></name><name><surname>Peng</surname><given-names>XP</given-names></name><name><surname>Clement</surname><given-names>C</given-names></name><name><surname>Rodina</surname><given-names>A</given-names></name><name><surname>Nieto</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>SM</given-names></name><name><surname>Maloney</surname><given-names>KN</given-names></name><name><surname>Clardy</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Chiosis</surname><given-names>G</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators</article-title><source>Cancer Cell</source><volume>10</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.005</pub-id><pub-id pub-id-type="pmid">17010675</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>AC</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Zollo</surname><given-names>O</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>ME</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name><name><surname>Meyuhas</surname><given-names>O</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic dissection of the oncogenic mtor pathway reveals druggable addiction to translational control via 4EBP-eif4e</article-title><source>Cancer Cell</source><volume>17</volume><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.021</pub-id><pub-id pub-id-type="pmid">20227039</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>A.C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Edlind</surname><given-names>MP</given-names></name><name><surname>Ingolia</surname><given-names>NT</given-names></name><name><surname>Janes</surname><given-names>MR</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>EY</given-names></name><name><surname>Stumpf</surname><given-names>CR</given-names></name><name><surname>Christensen</surname><given-names>C</given-names></name><name><surname>Bonham</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Jessen</surname><given-names>K</given-names></name><name><surname>Feldman</surname><given-names>ME</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Rommel</surname><given-names>C</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The translational landscape of mTOR signalling steers cancer initiation and metastasis</article-title><source>Nature</source><volume>485</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nature10912</pub-id><pub-id pub-id-type="pmid">22367541</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>A.C</given-names></name><name><surname>Nguyen</surname><given-names>HG</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Edlind</surname><given-names>MP</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra116</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aad5111</pub-id><pub-id pub-id-type="pmid">26577921</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>DB</given-names></name><name><surname>Henry</surname><given-names>GH</given-names></name><name><surname>Malewska</surname><given-names>A</given-names></name><name><surname>Iqbal</surname><given-names>NS</given-names></name><name><surname>Ruetten</surname><given-names>HM</given-names></name><name><surname>Turco</surname><given-names>AE</given-names></name><name><surname>Abler</surname><given-names>LL</given-names></name><name><surname>Sandhu</surname><given-names>SK</given-names></name><name><surname>Cadena</surname><given-names>MT</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Reese</surname><given-names>JC</given-names></name><name><surname>Mauck</surname><given-names>RJ</given-names></name><name><surname>Gahan</surname><given-names>JC</given-names></name><name><surname>Hutchinson</surname><given-names>RC</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Baker</surname><given-names>LA</given-names></name><name><surname>Vezina</surname><given-names>CM</given-names></name><name><surname>Strand</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Urethral luminal epithelia are castration-insensitive cells of the proximal prostate</article-title><source>The Prostate</source><volume>80</volume><fpage>872</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1002/pros.24020</pub-id><pub-id pub-id-type="pmid">32497356</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Shore</surname><given-names>ND</given-names></name><name><surname>Berger</surname><given-names>ER</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Penson</surname><given-names>DF</given-names></name><name><surname>Redfern</surname><given-names>CH</given-names></name><name><surname>Ferrari</surname><given-names>AC</given-names></name><name><surname>Dreicer</surname><given-names>R</given-names></name><name><surname>Sims</surname><given-names>RB</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Frohlich</surname><given-names>MW</given-names></name><name><surname>Schellhammer</surname><given-names>PF</given-names></name><name><surname>Investigators</surname><given-names>IS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>The New England Journal of Medicine</source><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthaus</surname><given-names>WR</given-names></name><name><surname>Hofree</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Linton</surname><given-names>EL</given-names></name><name><surname>Turkekul</surname><given-names>M</given-names></name><name><surname>Bejnood</surname><given-names>A</given-names></name><name><surname>Carver</surname><given-names>B</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Laudone</surname><given-names>V</given-names></name><name><surname>Biton</surname><given-names>M</given-names></name><name><surname>Chaudhary</surname><given-names>O</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Masilionis</surname><given-names>I</given-names></name><name><surname>Manova</surname><given-names>K</given-names></name><name><surname>Mazutis</surname><given-names>L</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regenerative potential of prostate luminal cells revealed by single-cell analysis</article-title><source>Science</source><volume>368</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1126/science.aay0267</pub-id><pub-id pub-id-type="pmid">32355025</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karzai</surname><given-names>F</given-names></name><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Wilkinson</surname><given-names>S</given-names></name><name><surname>Madan</surname><given-names>RA</given-names></name><name><surname>Shih</surname><given-names>JH</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Harmon</surname><given-names>SA</given-names></name><name><surname>VanderWeele</surname><given-names>DJ</given-names></name><name><surname>Cordes</surname><given-names>LM</given-names></name><name><surname>Carrabba</surname><given-names>NV</given-names></name><name><surname>Bright</surname><given-names>JR</given-names></name><name><surname>Terrigino</surname><given-names>NT</given-names></name><name><surname>Chun</surname><given-names>G</given-names></name><name><surname>Bilusic</surname><given-names>M</given-names></name><name><surname>Couvillon</surname><given-names>A</given-names></name><name><surname>Hankin</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>MN</given-names></name><name><surname>Lis</surname><given-names>RT</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Choyke</surname><given-names>PL</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name><name><surname>Sowalsky</surname><given-names>AG</given-names></name><name><surname>Turkbey</surname><given-names>B</given-names></name><name><surname>Pinto</surname><given-names>PA</given-names></name><name><surname>Dahut</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2344</pub-id><pub-id pub-id-type="pmid">33023952</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Keum</surname><given-names>YS</given-names></name><name><surname>Reddy</surname><given-names>B</given-names></name><name><surname>Conney</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>ANT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin</article-title><source>Carcinogenesis</source><volume>27</volume><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi272</pub-id><pub-id pub-id-type="pmid">16299382</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korbecki</surname><given-names>J</given-names></name><name><surname>Kojder</surname><given-names>K</given-names></name><name><surname>Simińska</surname><given-names>D</given-names></name><name><surname>Bohatyrewicz</surname><given-names>R</given-names></name><name><surname>Gutowska</surname><given-names>I</given-names></name><name><surname>Chlubek</surname><given-names>D</given-names></name><name><surname>Baranowska-Bosiacka</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cc chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>8412</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218412</pub-id><pub-id pub-id-type="pmid">33182504</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korsten</surname><given-names>H</given-names></name><name><surname>Ziel-van der Made</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>van der Kwast</surname><given-names>T</given-names></name><name><surname>Trapman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a PTEN knockout mouse prostate cancer model</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5662</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005662</pub-id><pub-id pub-id-type="pmid">19461893</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>SY</given-names></name><name><surname>Rosario</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>P</given-names></name><name><surname>Seshadri</surname><given-names>M</given-names></name><name><surname>Goodrich</surname><given-names>ZW</given-names></name><name><surname>Goodrich</surname><given-names>MM</given-names></name><name><surname>Labbé</surname><given-names>DP</given-names></name><name><surname>Gomez</surname><given-names>EC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name><name><surname>Goodrich</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Rb1 and trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance</article-title><source>Science</source><volume>355</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1126/science.aah4199</pub-id><pub-id pub-id-type="pmid">28059767</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>AT</given-names></name><name><surname>Wilkinson</surname><given-names>S</given-names></name><name><surname>Sowalsky</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comparison of approaches to transcriptomic analysis in multi-sampled tumors</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/bib/bbab337</pub-id><pub-id pub-id-type="pmid">34415294</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>OJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stem cell antigen-1 identifies a distinct androgen-independent murine prostatic luminal cell lineage with bipotent potential</article-title><source>Stem Cells</source><volume>34</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/stem.2217</pub-id><pub-id pub-id-type="pmid">26418304</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>O-J</given-names></name><name><surname>Choi</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Xin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Sca-1+ and sca-1− mouse prostatic luminal cell lineages are independently sustained</article-title><source>Stem Cells</source><volume>38</volume><fpage>1479</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1002/stem.3253</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>OJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Xin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from PTEN null Sca-1+ prostate luminal cells</article-title><source>Oncogene</source><volume>40</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01526-2</pub-id><pub-id pub-id-type="pmid">33110232</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrecque</surname><given-names>MP</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Kollath</surname><given-names>L</given-names></name><name><surname>Lakely</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>da Costa</surname><given-names>RMG</given-names></name><name><surname>Kaipainen</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>R</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name><name><surname>Mostaghel</surname><given-names>EA</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Schweizer</surname><given-names>MT</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name><name><surname>Lin</surname><given-names>DW</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>4492</fpage><lpage>4505</lpage><pub-id pub-id-type="doi">10.1172/JCI128212</pub-id><pub-id pub-id-type="pmid">31361600</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>JJ</given-names></name><name><surname>Lai</surname><given-names>KP</given-names></name><name><surname>Chuang</surname><given-names>KH</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>IC</given-names></name><name><surname>Lin</surname><given-names>WJ</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>3739</fpage><lpage>3751</lpage><pub-id pub-id-type="doi">10.1172/JCI39335</pub-id><pub-id pub-id-type="pmid">19907077</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Soldatov</surname><given-names>R</given-names></name><name><surname>Zeisel</surname><given-names>A</given-names></name><name><surname>Braun</surname><given-names>E</given-names></name><name><surname>Hochgerner</surname><given-names>H</given-names></name><name><surname>Petukhov</surname><given-names>V</given-names></name><name><surname>Lidschreiber</surname><given-names>K</given-names></name><name><surname>Kastriti</surname><given-names>ME</given-names></name><name><surname>Lönnerberg</surname><given-names>P</given-names></name><name><surname>Furlan</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Borm</surname><given-names>LE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>van Bruggen</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Barker</surname><given-names>R</given-names></name><name><surname>Sundström</surname><given-names>E</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name><name><surname>Cramer</surname><given-names>P</given-names></name><name><surname>Adameyko</surname><given-names>I</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name><name><surname>Kharchenko</surname><given-names>PV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rna velocity of single cells</article-title><source>Nature</source><volume>560</volume><fpage>494</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0414-6</pub-id><pub-id pub-id-type="pmid">30089906</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>Y</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Schuster</surname><given-names>SL</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Fitzgibbon</surname><given-names>M</given-names></name><name><surname>Wladyka</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Delrow</surname><given-names>JJ</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multiplexed functional genomic analysis of 5’ untranslated region mutations across the spectrum of prostate cancer</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4217</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24445-6</pub-id><pub-id pub-id-type="pmid">34244513</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Grogan</surname><given-names>TR</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Mottahedeh</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Stoyanova</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Shkhyan</surname><given-names>RO</given-names></name><name><surname>Nowroozizadeh</surname><given-names>B</given-names></name><name><surname>Rettig</surname><given-names>MB</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Elashoff</surname><given-names>D</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name><name><surname>Goldstein</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome</article-title><source>Cell Reports</source><volume>17</volume><fpage>2596</fpage><lpage>2606</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.010</pub-id><pub-id pub-id-type="pmid">27926864</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Horn</surname><given-names>JL</given-names></name><name><surname>Banda</surname><given-names>K</given-names></name><name><surname>Goodman</surname><given-names>AZ</given-names></name><name><surname>Lim</surname><given-names>Y</given-names></name><name><surname>Jana</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Germanos</surname><given-names>AA</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Hardin</surname><given-names>WR</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Tharakan</surname><given-names>RG</given-names></name><name><surname>Cai</surname><given-names>EY</given-names></name><name><surname>Uo</surname><given-names>T</given-names></name><name><surname>Pillai</surname><given-names>SPS</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Carver</surname><given-names>BS</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Beronja</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The androgen receptor regulates a druggable translational regulon in advanced prostate cancer</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaaw4993</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw4993</pub-id><pub-id pub-id-type="pmid">31366581</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Bujanda</surname><given-names>ZA</given-names></name><name><surname>Haffner</surname><given-names>MC</given-names></name><name><surname>Chaimowitz</surname><given-names>MG</given-names></name><name><surname>Chowdhury</surname><given-names>N</given-names></name><name><surname>Venturini</surname><given-names>NJ</given-names></name><name><surname>Patel</surname><given-names>RA</given-names></name><name><surname>Obradovic</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>CS</given-names></name><name><surname>Jacków</surname><given-names>J</given-names></name><name><surname>Maynard</surname><given-names>JP</given-names></name><name><surname>Sfanos</surname><given-names>KS</given-names></name><name><surname>Abate-Shen</surname><given-names>C</given-names></name><name><surname>Bieberich</surname><given-names>CJ</given-names></name><name><surname>Hurley</surname><given-names>PJ</given-names></name><name><surname>Selby</surname><given-names>MJ</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression</article-title><source>Nature Cancer</source><volume>2</volume><fpage>803</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1038/s43018-021-00227-3</pub-id><pub-id pub-id-type="pmid">35122025</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>TL</given-names></name><name><surname>Huang</surname><given-names>YF</given-names></name><name><surname>You</surname><given-names>LR</given-names></name><name><surname>Chao</surname><given-names>NC</given-names></name><name><surname>Su</surname><given-names>FY</given-names></name><name><surname>Chang</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conditionally ablated PTEN in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice</article-title><source>The American Journal of Pathology</source><volume>182</volume><fpage>975</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.11.025</pub-id><pub-id pub-id-type="pmid">23313138</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Riesenfeld</surname><given-names>S</given-names></name><name><surname>Andrews</surname><given-names>T</given-names></name><name><surname>Dao</surname><given-names>TP</given-names></name><name><surname>Gomes</surname><given-names>T</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><collab>participants in the 1st Human Cell Atlas Jamboree</collab></person-group><year iso-8601-date="2019">2019</year><article-title>EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1662-y</pub-id><pub-id pub-id-type="pmid">30902100</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>E</given-names></name><name><surname>Moline</surname><given-names>D</given-names></name><name><surname>VanOpstall</surname><given-names>C</given-names></name><name><surname>Lamperis</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Vander Griend</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sox2 expression marks castration-resistant progenitor cells in the adult murine prostate</article-title><source>Stem Cells</source><volume>37</volume><fpage>690</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1002/stem.2987</pub-id><pub-id pub-id-type="pmid">30720908</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mevel</surname><given-names>R</given-names></name><name><surname>Steiner</surname><given-names>I</given-names></name><name><surname>Mason</surname><given-names>S</given-names></name><name><surname>Galbraith</surname><given-names>LC</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Fadlullah</surname><given-names>MZ</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Leung</surname><given-names>HY</given-names></name><name><surname>Oliveira</surname><given-names>P</given-names></name><name><surname>Blyth</surname><given-names>K</given-names></name><name><surname>Baena</surname><given-names>E</given-names></name><name><surname>Lacaud</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Runx1 marks a luminal castration-resistant lineage established at the onset of prostate development</article-title><source>eLife</source><volume>9</volume><elocation-id>e60225</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60225</pub-id><pub-id pub-id-type="pmid">33025905</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizokami</surname><given-names>A</given-names></name><name><surname>Gotoh</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line</article-title><source>The Journal of Urology</source><volume>164</volume><fpage>800</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1097/00005392-200009010-00053</pub-id><pub-id pub-id-type="pmid">10953159</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>KL</given-names></name><name><surname>Sheahan</surname><given-names>AV</given-names></name><name><surname>Burkhart</surname><given-names>DL</given-names></name><name><surname>Baca</surname><given-names>SC</given-names></name><name><surname>Boufaied</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Cañadas</surname><given-names>I</given-names></name><name><surname>Roehle</surname><given-names>K</given-names></name><name><surname>Heckler</surname><given-names>M</given-names></name><name><surname>Calagua</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Pantelidou</surname><given-names>C</given-names></name><name><surname>Galbo</surname><given-names>P</given-names></name><name><surname>Panja</surname><given-names>S</given-names></name><name><surname>Mitrofanova</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>S</given-names></name><name><surname>Whitlock</surname><given-names>NC</given-names></name><name><surname>Trostel</surname><given-names>SY</given-names></name><name><surname>Hamid</surname><given-names>AA</given-names></name><name><surname>Kibel</surname><given-names>AS</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Choudhury</surname><given-names>AD</given-names></name><name><surname>Pomerantz</surname><given-names>MM</given-names></name><name><surname>Sweeney</surname><given-names>CJ</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Einstein</surname><given-names>DJ</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Dougan</surname><given-names>SK</given-names></name><name><surname>Sowalsky</surname><given-names>AG</given-names></name><name><surname>He</surname><given-names>HH</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Labbé</surname><given-names>DP</given-names></name><name><surname>Olson</surname><given-names>BM</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ezh2 inhibition activates a dsrna-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer</article-title><source>Nature Cancer</source><volume>2</volume><fpage>444</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/s43018-021-00185-w</pub-id><pub-id pub-id-type="pmid">33899001</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Network</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular taxonomy of primary prostate cancer</article-title><source>Cell</source><volume>163</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id><pub-id pub-id-type="pmid">26544944</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chawla</surname><given-names>R</given-names></name><name><surname>Pliner</surname><given-names>HA</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Reversed graph embedding resolves complex single-cell trajectories</article-title><source>Nature Methods</source><volume>14</volume><fpage>979</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4402</pub-id><pub-id pub-id-type="pmid">28825705</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaglia</surname><given-names>F</given-names></name><name><surname>Krishn</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Goodrich</surname><given-names>DW</given-names></name><name><surname>McCue</surname><given-names>P</given-names></name><name><surname>Kossenkov</surname><given-names>AV</given-names></name><name><surname>Mandigo</surname><given-names>AC</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name><name><surname>Weinreb</surname><given-names>PH</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>WK</given-names></name><name><surname>Languino</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0244985</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0244985</pub-id><pub-id pub-id-type="pmid">33481853</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sackmann Sala</surname><given-names>L</given-names></name><name><surname>Boutillon</surname><given-names>F</given-names></name><name><surname>Menara</surname><given-names>G</given-names></name><name><surname>De Goyon-Pélard</surname><given-names>A</given-names></name><name><surname>Leprévost</surname><given-names>M</given-names></name><name><surname>Codzamanian</surname><given-names>J</given-names></name><name><surname>Lister</surname><given-names>N</given-names></name><name><surname>Pencik</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Bole-Feysot</surname><given-names>C</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Risbridger</surname><given-names>GP</given-names></name><name><surname>Taylor</surname><given-names>RA</given-names></name><name><surname>Kenner</surname><given-names>L</given-names></name><name><surname>Guidotti</surname><given-names>J-E</given-names></name><name><surname>Goffin</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A rare castration-resistant progenitor cell population is highly enriched in PTEN-null prostate tumours</article-title><source>The Journal of Pathology</source><volume>243</volume><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/path.4924</pub-id><pub-id pub-id-type="pmid">28603917</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>B</given-names></name><name><surname>Bluestone</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation</article-title><source>Annual Review of Immunology</source><volume>19</volume><fpage>225</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.225</pub-id><pub-id pub-id-type="pmid">11244036</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>SL</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The untranslated regions of mRNAs in cancer</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.02.011</pub-id><pub-id pub-id-type="pmid">30961831</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setty</surname><given-names>M</given-names></name><name><surname>Kiseliovas</surname><given-names>V</given-names></name><name><surname>Levine</surname><given-names>J</given-names></name><name><surname>Gayoso</surname><given-names>A</given-names></name><name><surname>Mazutis</surname><given-names>L</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterization of cell fate probabilities in single-cell data with palantir</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0068-4</pub-id><pub-id pub-id-type="pmid">30899105</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Nastiuk</surname><given-names>KL</given-names></name><name><surname>Krolewski</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tnf signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures</article-title><source>Oncotarget</source><volume>6</volume><fpage>25726</fpage><lpage>25740</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4535</pub-id><pub-id pub-id-type="pmid">26327448</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>MM</given-names></name><name><surname>Abate-Shen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular genetics of prostate cancer: new prospects for old challenges</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1967</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1101/gad.1965810</pub-id><pub-id pub-id-type="pmid">20844012</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fuchs</surname><given-names>HE</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer statistics, 2021</article-title><source>CA</source><volume>71</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Weinstein</surname><given-names>HNW</given-names></name><name><surname>Allegakoen</surname><given-names>P</given-names></name><name><surname>Wadsworth</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Castro</surname><given-names>EA</given-names></name><name><surname>Lu</surname><given-names>KL</given-names></name><name><surname>Stohr</surname><given-names>BA</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Cooperberg</surname><given-names>MR</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>141</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-27322-4</pub-id><pub-id pub-id-type="pmid">35013146</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stultz</surname><given-names>J</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer</article-title><source>Prostate Cancer and Prostatic Diseases</source><volume>24</volume><fpage>697</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1038/s41391-021-00340-5</pub-id><pub-id pub-id-type="pmid">33820953</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>RU</given-names></name><name><surname>Haverkamp</surname><given-names>JM</given-names></name><name><surname>Thedens</surname><given-names>DR</given-names></name><name><surname>Cohen</surname><given-names>MB</given-names></name><name><surname>Ratliff</surname><given-names>TL</given-names></name><name><surname>Henry</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Slow disease progression in a C57BL/6 PTEN-deficient mouse model of prostate cancer</article-title><source>The American Journal of Pathology</source><volume>179</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.014</pub-id><pub-id pub-id-type="pmid">21703427</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Carver</surname><given-names>BS</given-names></name><name><surname>Arora</surname><given-names>VK</given-names></name><name><surname>Kaushik</surname><given-names>P</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Mitsiades</surname><given-names>N</given-names></name><name><surname>Landers</surname><given-names>T</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Major</surname><given-names>JE</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Lash</surname><given-names>AE</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Eastham</surname><given-names>JA</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Integrative genomic profiling of human prostate cancer</article-title><source>Cancer Cell</source><volume>18</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.05.026</pub-id><pub-id pub-id-type="pmid">20579941</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Cacchiarelli</surname><given-names>D</given-names></name><name><surname>Grimsby</surname><given-names>J</given-names></name><name><surname>Pokharel</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/nbt.2859</pub-id><pub-id pub-id-type="pmid">24658644</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>Q</given-names></name><name><surname>Rozengurt</surname><given-names>N</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Roy-Burman</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Prostate-Specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer</article-title><source>Cancer Cell</source><volume>4</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00215-0</pub-id><pub-id pub-id-type="pmid">14522255</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>AJ</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Lawson</surname><given-names>DA</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation</article-title><source>PNAS</source><volume>103</volume><fpage>1480</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510652103</pub-id><pub-id pub-id-type="pmid">16432235</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZA</given-names></name><name><surname>Mitrofanova</surname><given-names>A</given-names></name><name><surname>Bergren</surname><given-names>SK</given-names></name><name><surname>Abate-Shen</surname><given-names>C</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/ncb2697</pub-id><pub-id pub-id-type="pmid">23434823</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>PA</given-names></name><name><surname>Arora</surname><given-names>VK</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer</article-title><source>Nature Reviews. Cancer</source><volume>15</volume><fpage>701</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1038/nrc4016</pub-id><pub-id pub-id-type="pmid">26563462</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Karzai</surname><given-names>F</given-names></name><name><surname>Harmon</surname><given-names>SA</given-names></name><name><surname>Terrigino</surname><given-names>NT</given-names></name><name><surname>VanderWeele</surname><given-names>DJ</given-names></name><name><surname>Bright</surname><given-names>JR</given-names></name><name><surname>Atway</surname><given-names>R</given-names></name><name><surname>Trostel</surname><given-names>SY</given-names></name><name><surname>Carrabba</surname><given-names>NV</given-names></name><name><surname>Whitlock</surname><given-names>NC</given-names></name><name><surname>Walker</surname><given-names>SM</given-names></name><name><surname>Lis</surname><given-names>RT</given-names></name><name><surname>Abdul Sater</surname><given-names>H</given-names></name><name><surname>Capaldo</surname><given-names>BJ</given-names></name><name><surname>Madan</surname><given-names>RA</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name><name><surname>Chun</surname><given-names>G</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Pinto</surname><given-names>PA</given-names></name><name><surname>Salles</surname><given-names>DC</given-names></name><name><surname>Kaur</surname><given-names>HB</given-names></name><name><surname>Lotan</surname><given-names>TL</given-names></name><name><surname>Venzon</surname><given-names>DJ</given-names></name><name><surname>Choyke</surname><given-names>PL</given-names></name><name><surname>Turkbey</surname><given-names>B</given-names></name><name><surname>Dahut</surname><given-names>WL</given-names></name><name><surname>Sowalsky</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy</article-title><source>European Urology</source><volume>80</volume><fpage>746</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2021.03.009</pub-id><pub-id pub-id-type="pmid">33785256</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>L</given-names></name><name><surname>Lawson</surname><given-names>DA</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis</article-title><source>PNAS</source><volume>102</volume><fpage>6942</fpage><lpage>6947</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502320102</pub-id><pub-id pub-id-type="pmid">15860580</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Ju</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>537</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-02752-y</pub-id><pub-id pub-id-type="pmid">32678075</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaynagetdinov</surname><given-names>R</given-names></name><name><surname>Sherrill</surname><given-names>TP</given-names></name><name><surname>Polosukhin</surname><given-names>VV</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Ausborn</surname><given-names>JA</given-names></name><name><surname>McLoed</surname><given-names>AG</given-names></name><name><surname>McMahon</surname><given-names>FB</given-names></name><name><surname>Gleaves</surname><given-names>LA</given-names></name><name><surname>Degryse</surname><given-names>AL</given-names></name><name><surname>Stathopoulos</surname><given-names>GT</given-names></name><name><surname>Yull</surname><given-names>FE</given-names></name><name><surname>Blackwell</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A critical role for macrophages in promotion of urethane-induced lung carcinogenesis</article-title><source>Journal of Immunology</source><volume>187</volume><fpage>5703</fpage><lpage>5711</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100558</pub-id><pub-id pub-id-type="pmid">22048774</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79076.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Nima</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Cleveland Clinic</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.03.02.482711" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.02.482711"/></front-stub><body><p>Prostate cancer cellular heterogeneity is a major problem for disease progression and treatment resistance. This body of work addresses the cellular identity and populations that make up prostate cancer using single-cell sequencing technology, state-of-the-art mouse models and connections to human prostate cancer. The cellular identities, associated signaling networks, and immune complexes accompanying the heterogeneity of the prostate are identified in this work and a resource is provided for scientists in the field.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79076.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sharifi</surname><given-names>Nima</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Cleveland Clinic</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Strand</surname><given-names>Douglas</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.02.482711">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.03.02.482711v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Defining cellular population dynamics at single cell resolution during prostate cancer progression&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and W Kimryn Rathmell as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Douglas Strand (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>This manuscript has significant strengths that could make it an asset to the field. However, there are also deficiencies that need to be addressed and require major revisions. Based on the referee evaluations, the following are the major points that need to be addressed:</p><p>1) The 'intermediate' cell state observed in the intact and castrated PTEN model is not observed in primary prostate cancer and there is little sc evidence yet in advanced cancer to compare it to.</p><p>2) There should be some additional emphasis placed on the human level validation for the central findings in this work.</p><p>3) Please address the deficiencies of using the PB-Cre-PTEN model as detailed by the reviewers.</p><p>4) Please address the limitations of using trajectory analysis. Please see reviewer 2 comments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The study focuses on a clinically highly relevant and timely topic. The strength of this manuscript is the meticulous description of the Methods and model development and the integration of state-of-the-art orthogonal data sets. However, the number of data-points across the experiments (n = 2 or 3) with considerable variability in the Ptenfl/fl group limits the interpretation of findings. Additionally, further experiments are needed to validate these observations in a human prostate cancer and establish potential translational relevance of these findings. As such, the report is fairly descriptive and expanding the discussion on the mechanistic studies needed to identify which of these interactions drives aggressive prostate cancer would improve this report.</p><p>Pg 6, lines 254-256. Where is the role of epithelial cells discussed and supported by findings?</p><p>Pg 7, lines 279-280. I'm not sure that &quot;early on in cancer&quot; is supported by the data. Experiments focused on signaling patterns and cell-to-cell interactions, but time course of disease isn't shown/emphasized until the conclusion statement.</p><p>Pg 7, lines 290-304. AR activity in intermediate cells was compared between WT, intact and castrated PTEN-null samples. Line 300, differentiated cells retain high AR activity in intact PTEN-null but because population is absent in castrate mice (line 296), how is final conclusion about &quot;luminal cells&quot;, broadly, arrived at?</p><p>Pg 8, lines 339-363. Were the TCGA cohorts confirmed PTEN loss? Please clarify and mention limitations when comparing DEGs in mice with human cohorts.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Unfortunately, the expansion of an intermediate cell state in Pten null mice (PMID: 28603917) or castrated mice (PMID: 32355025) is not very new and diminishes the impact. Also, the stem cell story has evolved quite a bit since 2016. 'Intermediate luminal cells' in the proximal prostate are preexisting Krt4+ urethral cells (PMID: 32497356). This is only a 'rare, but distinct population' in the prostate. In contrast, the entire urethra is also composed of these cells. Lineage tracing of these proximal cells during castration/regeneration shows that they do NOT give rise to prostate luminal cells even though they form spheroids at a higher rate (PMID: 32355025, 32807988). Instead, preexisting prostate luminal cells undergo lineage plasticity to resemble urethral/intermediate luminal cells (yes, it's confusing – why would a cell adapt to resemble a cell type that isn't a progenitor for it? – I don't know). Accordingly, it is inaccurate to say that these preexisting cells 'fill an important regenerative niche' until there is opposing evidence. We all know that RNA velocity can make anything look like a progenitor. Also, the urothelium of the bladder also expresses Psca, Trop2, and Krt4 and can regenerate prostate tissue in tissue recombination assays – this does not mean that bladder urothelium is a prostate progenitor.</p><p>The use of the term 'intermediate' luminal as a descriptive term for the plastic state of prostate luminal cells during castration, cancer is just ok. However, this must be distinguished from 'urethral' luminal epithelia, which are a pre-existing proximal cell type in the urethra and proximal ducts of the intact prostate that does not express NKX3-1 or probasin. The key is to figure out how/why prostate luminal cells adapt to look like (and cluster with) urothelium under pten inactivation or castration (perhaps KL5? PMID: 34737261). Unfortunately, I think the leaky inactivation of Pten in basal and urethral luminal cells is confounding this question in this model. Accordingly, is there any solid evidence yet of basal epithelia acquiring mutations in human prostate cancer (notwithstanding the experimental evidence from Goldstein)?</p><p>What would be interesting is to highlight the molecular difference between lineage plastic prostate luminal cells in the castrate WT and intact Pten null mice and compare to the intact WT proximal urethral cell signature. This would give us an idea of how similar the lineage plastic state is under the 2 different conditions (I agree with your suggestion that pten inactivation could simply reduce Ar activity, making it undergo similar lineage plasticity to an 'intermediate' state). In summary, make sure to distinguish between the preexisting proximal urethral luminal cells that don't give rise to prostate luminal cells during castration/regeneration and the 'intermediate' prostate luminal cells that underwent plasticity under castration and Pten inactivation and can likely regain prostate differentiation when androgens are replenished.</p><p>Figure 1: The proposition that basal cells are differentiating into intermediate luminal cells is intriguing, but could just as easily be an artifact of trajectory analysis (which is notoriously misleading) or the activation of Pten in basal epithelia (which is not yet known to happen in human prostate cancer as far as I know). It also defies the current paradigm that prostate luminal epithelia undergo lineage plasticity in castration and when mutated. Therefore, I would suggest hedging this bet in the conclusion.</p><p>Figure 3: While intermediate/urethral epithelia may be AR+ in WT mice, their expression of probasin and NKX3-1 is null. Thus, the AR composite score is misleading in Figure 3D. Moreover, how would the AR score be higher in intermediate/urethral epithelia than in differentiated luminal cells in WT mice??? It would seem the Hieronymus score from LNCaP cells is inappropriately used here as a measure of ALL AR activity and not a measure of prostate luminal-specific AR activity. A more accurate score would be to use probasin expression itself or a signature generated from WT vs. castrated mice (PMID: 32355025).</p><p>The color coding of the subclustered intermediate epithelia in 3E does not seem to match the quantitation in 3F. This confuses the interpretation of 3G as well. It seems likely that the heterogeneity of cells identified as intermediate epithelia could reflect cells that are transdifferentiating from basal due to promiscuous Pten inactivation as well as from lineage plasticity of Pten inactivation in prostate luminal cells. It would be really useful to see how these clusters compare to the castrate ventral lobe in a WT mouse. It would also be useful to see the AR activity of these clusters relative to intact prostate basal and luminal cells in Figure 3G.</p><p>I'm not sure that the observation that castration increases the number of AR-low intermediate cells necessarily means that this is a selection of a pre-existing state since we know that pre-existing prostate luminal epithelia can undergo lineage plasticity in response to castration in the non-tumorigenic setting.</p><p>The observation that the castrate Pten intermediate epithelial signature is enriched in aggressive disease (compared to intact Pten intermediate) is not too surprising as this may just reflect castration. What would be interesting is to know how this model compares to other models of castration resistance like Rb/p53 null mice.</p><p>Discussion:</p><p>Line 488: While it's true that the transdifferentiation, an intermediate luminal phenotype is absent in the (intact) wild-type mouse, this phenotype does appear in castrate WT mice. This is not a cancer-specific lineage transition as this also happens in 5ARI-treated men (PMID 34928497).</p><p>Line 499: I'm not convinced that these data suggest that specific portions of the intermediate compartment are responsible for their expansion. Without lineage tracing in humans, it's impossible to know whether the change in heterogeneity is the result of increased transdifferentiation of both basal and luminal cells. This may be artificially induced by the promiscuous PB4-Cre promoter rather than a reflection of human prostate cancer as the level of CNVs in basal epithelia in primary tumors appears to be low.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79076.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>This manuscript has significant strengths that could make it an asset to the field. However, there are also deficiencies that need to be addressed and require major revisions. Based on the referee evaluations, the following are the major points that need to be addressed:</p><p>1) The 'intermediate' cell state observed in the intact and castrated PTEN model is not observed in primary prostate cancer and there is little sc evidence yet in advanced cancer to compare it to.</p></disp-quote><p>We thank the reviewers for pointing out a potential pitfall of our study. In response, we have now analyzed human patient-based scRNAseq data from localized (Song et al., Nat Comms 2022) and metastatic prostate cancer (Dong et al., Comms Bio 2020). We found that the gene signatures derived from our intermediate cells are enriched in the setting of castration resistant prostate cancer (Figure 4D-E). We conclude that an intermediate-like state likely exists in advanced human prostate cancer and potentially contributes to patient outcomes.</p><disp-quote content-type="editor-comment"><p>2) There should be some additional emphasis placed on the human level validation for the central findings in this work.</p></disp-quote><p>We agree with the reviewers that further confirmation that our findings apply to human disease would strengthen this manuscript. As such, we have added single-cell RNA-seq data of human tumors to validate our observations. We used data from multiple human studies (Song et al., Nat Comms 2022; Dong et al., Comms Bio 2020) to compare primary and metastatic prostate cancer. We show that our 5-gene treatment resistance signature from our murine dataset correlates with a subset of cells from 6 human metastatic prostate cancers but is completely absent in localized disease (Figure 4D-E). We conclude that castrated intermediate cells correlate to a cell state found in human metastatic castration resistant prostate cancer tumors, and that this subset may contribute to ADT resistance.</p><disp-quote content-type="editor-comment"><p>3) Please address the deficiencies of using the PB-Cre-PTEN model as detailed by the reviewers.</p></disp-quote><p>We thank the reviewers for pointing this out. To address the deficiencies of using the <italic>PB-Cre-Pten</italic> model, we have now conducted additional analyses across orthogonal models and patient cohorts. In particular, we have validated our key findings in another series of mouse models of castration-resistant prostate cancer (Brady et al., Nat Comms 2021) and have used public patient datasets (TCGA, Taylor) as well as single-cell sequencing data from primary and metastatic prostate cancer patients (Song et al., Nat Comms 2022; Dong et al., Comms Bio 2020) to correlate our observations to clinically relevant models (Figure 4D-G). In addition, we discuss that the PB-Cre driver is active in multiple epithelial subtypes in the <italic>Pten<sup>fl/fl</sup></italic> model, and therefore new lineage tracing studies will be required to determine the origins of the intermediate cell states (Lines 617-629).</p><disp-quote content-type="editor-comment"><p>4) Please address the limitations of using trajectory analysis. Please see reviewer 2 comments.</p></disp-quote><p>We agree with the reviewers that trajectory analysis alone is not sufficient to establish cellular lineages and phenotype switches. We have updated our analysis of our data and integrated further literature to speculate about the cellular origins of intermediate cells in the <italic>Pten</italic> loss model (Lines 262-276), and believe our hypotheses are now in line with the state of the field. We have edited the text to clarify the need for in-tissue validation of our computational findings (Lines 274-276, 626-629).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The study focuses on a clinically highly relevant and timely topic. The strength of this manuscript is the meticulous description of the Methods and model development and the integration of state-of-the-art orthogonal data sets. However, the number of data-points across the experiments (n = 2 or 3) with considerable variability in the Ptenfl/fl group limits the interpretation of findings. Additionally, further experiments are needed to validate these observations in a human prostate cancer and establish potential translational relevance of these findings. As such, the report is fairly descriptive and expanding the discussion on the mechanistic studies needed to identify which of these interactions drives aggressive prostate cancer would improve this report.</p></disp-quote><p>We are ecstatic that the reviewer finds our study “clinically highly relevant.” We agree that the low sample size is a potential limitation but believe that our overall results are robust and enable concrete conclusions for both epithelial and immune cell populations. This is in part because we validated our findings in orthogonal human datasets (Figure 4A-C, Figure 5H) in the original manuscript. However, to add rigor to our study, we have conducted new scRNAseq analysis showing that our findings correlate well with both human patient data (Figure 4D-E) and orthogonal mouse models (Figure 4F-G). Furthermore, we conducted additional scRNAseq on castrated WT murine prostate to demonstrate how castration plays an important role in translational heterogeneity in intermediate cells (Figure 4H, Figure 3–figure supplement 1G).</p><disp-quote content-type="editor-comment"><p>As such, the report is fairly descriptive, and expanding the discussion on the mechanistic studies needed to identify which of these interactions drives aggressive prostate cancer would improve this report.</p></disp-quote><p>We agree with the reviewer that additional discussion of follow-up studies is necessary. As such, we have updated the discussion to highlight the molecular studies needed to fully characterize the cellular phenotypes described in this manuscript (Lines 626-629, 643-644, 658- 660, 676-678).</p><disp-quote content-type="editor-comment"><p>Pg 6, lines 254-256. Where is the role of epithelial cells discussed and supported by findings?</p></disp-quote><p>We outline epithelial-macrophage signaling interactions in lines 310-315 (highlighted in the text), showing both the presence of ligand-receptor interactions and the increased expression of epithelial ligands in Ptenfl/fl mice.</p><disp-quote content-type="editor-comment"><p>Pg 7, lines 279-280. I'm not sure that &quot;early on in cancer&quot; is supported by the data. Experiments focused on signaling patterns and cell-to-cell interactions, but time course of disease isn't shown/emphasized until the conclusion statement.</p></disp-quote><p>We thank the reviewer for pointing out this passage, as we agree that it is impossible to infer accurate temporal dynamics from our data. We have rephrased the passage to more precisely reflect the nature of our observations (Lines 350-351).</p><disp-quote content-type="editor-comment"><p>Pg 7, lines 290-304. AR activity in intermediate cells was compared between WT, intact and castrated PTEN-null samples. Line 300, differentiated cells retain high AR activity in intact PTEN-null but because population is absent in castrate mice (line 296), how is final conclusion about &quot;luminal cells&quot;, broadly, arrived at?</p></disp-quote><p>We thank the reviewer for pointing out confusing language in the text. We have updated both Figure 3D and the text to better reflect our hypothesis. Specifically, we find that while intermediate cells exhibit a lower reliance on AR signaling upon Pten loss, differentiated luminal cells do not. We have also added speculation that the ablation of differentiated luminal cells in Ptenfl/fl castrate mice could be due to lineage plasticity rather than apoptosis in response to AR deprivation (Lines 374-378).</p><disp-quote content-type="editor-comment"><p>Pg 8, lines 339-363. Were the TCGA cohorts confirmed PTEN loss? Please clarify and mention limitations when comparing DEGs in mice with human cohorts.</p></disp-quote><p>The original plot was not filtered by PTEN status. We agree with the reviewer that stratifying the data for PTEN loss would be valuable and reanalyzed the data with this in mind. We find that filtering patients for either PTEN loss or amplification of the PI3K/AKT pathway in the TCGA data yields similar results, where patients overexpressing any of the 5 genes of interest have significantly lowered disease-free survival (Figure 4 – figure supplement 1D). The Taylor dataset did not have a large enough sample size for this stratification strategy to yield robust data.</p><p>We also recognize that comparing specific DEGs across species can lead to artifacts. As such, we have now validated our 5-gene signature in two additional systems. First, using scRNAseq data from localized (Song et al., Nat Comms 2022) and metastatic (Dong et al., Comms Bio 2020) prostate cancer patients, we found that only the latter had cancer cells enriched for the 5- gene signature (Figure 4D-E). Second, using a completely different progression model of murine prostate cancer (Brady et al., Nat Comms 2021), we found that the 5-gene signature correlated with advanced murine prostate cancer (Figure 4F-G). These data demonstrate the robustness of our original findings and overcome some of the limitations when comparing DEGs across mice and men.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Unfortunately, the expansion of an intermediate cell state in Pten null mice (PMID: 28603917) or castrated mice (PMID: 32355025) is not very new and diminishes the impact.</p></disp-quote><p>We agree with the reviewer that the presence of intermediate cells in the <italic>Pten<sup>fl/fl</sup></italic> mouse model is not novel. However, our findings go far beyond just identifying an intermediate population that expands during castration. In particular, we show that intermediate cells exhibit increased heterogeneity in the context of castration and may originate from multiple cellular sources in the <italic>Pten<sup>fl/fl</sup></italic> model. We also show that the castrate <italic>Pten<sup>fl/fl</sup></italic> intermediate cell state is associated with human prostate cancer metastasis (Figure 4D-E), worse outcomes in prostate cancer patients (Figure 4A-C, Figure 4 —figure supplement 1C-D), and can be seen in an entirely different murine model of advanced prostate cancer (Figure 4F-G). Thus, our work adds to the growing understanding of <italic>Pten<sup>fl/fl</sup></italic> intermediate cell dynamics and its relevance to human disease.</p><disp-quote content-type="editor-comment"><p>Also, the stem cell story has evolved quite a bit since 2016. 'Intermediate luminal cells' in the proximal prostate are preexisting Krt4+ urethral cells (PMID: 32497356). This is only a 'rare, but distinct population' in the prostate. In contrast, the entire urethra is also composed of these cells. Lineage tracing of these proximal cells during castration/regeneration shows that they do NOT give rise to prostate luminal cells even though they form spheroids at a higher rate (PMID: 32355025, 32807988). Instead, preexisting prostate luminal cells undergo lineage plasticity to resemble urethral/intermediate luminal cells (yes, it's confusing – why would a cell adapt to resemble a cell type that isn't a progenitor for it? – I don't know). Accordingly, it is inaccurate to say that these preexisting cells 'fill an important regenerative niche' until there is opposing evidence. We all know that RNA velocity can make anything look like a progenitor. Also, the urothelium of the bladder also expresses Psca, Trop2, and Krt4 and can regenerate prostate tissue in tissue recombination assays – this does not mean that bladder urothelium is a prostate progenitor.</p></disp-quote><p>We thank the reviewer for this detailed response and agree on the need to distinguish between urethral progenitor cells and native prostatic cells. We had previously excluded a cluster of cells from our dataset that we had identified as urethral cells; we re-included this cluster and confirmed that it primarily exists in WT intact mice and expresses urethral markers such as <italic>Psca</italic> and <italic>Krt4</italic> (Figure 1 —figure supplement 1C-D). We also compared this cluster to the previously described “intermediate” cluster in the WT intact mice and showed that the new urethral cluster, unlike the “intermediate” WT cluster, expresses the urethral markers <italic>Aqp3</italic> and <italic>Ly6d</italic> but not luminal progenitor markers <italic>Ppp1r1b</italic> and <italic>Clu</italic> (Figure 1 —figure supplement 1C), and do not cluster with WT “intermediate” cells (Figure 1 —figure supplement 1D). This matches well with published data identifying urethral and prostatic <italic>Krt4+</italic> cells in murine proximal prostates (Crowley et al., <italic>eLife</italic> 2020). In addition, the urethral cluster exhibits weaker expression of prostate epithelial and luminal markers (<italic>Epcam</italic>/<italic>Krt18</italic>/<italic>Krt8</italic>) (Figure 1 —figure supplement 1H). These results indicate that while the excluded cluster is likely urethral in nature, the previously included WT “intermediate” cluster, which is <italic>Epcam/Krt18/Krt8</italic> positive, may be composed of prostatic cells. Based on this analysis, we believe the previously named WT “intermediate” cluster may correspond to the proximal <italic>Krt4+</italic> cells described in Crowley et al. (<italic>eLife</italic> 2020) and the distal progenitor cells found in Guo et al. (Nat Genetics 2020). As such, we have re-named the WT “intermediate” cells to “luminal progenitor” cells (Figure 1 —figure supplement 1D). Moreover, given that urethral cells do not give rise to prostatic cells and are thus uninvolved in prostate cellular dynamics, we excluded this cluster from further analysis.</p><disp-quote content-type="editor-comment"><p>The use of the term 'intermediate' luminal as a descriptive term for the plastic state of prostate luminal cells during castration, cancer is just ok. However, this must be distinguished from 'urethral' luminal epithelia, which are a pre-existing proximal cell type in the urethra and proximal ducts of the intact prostate that does not express NKX3-1 or probasin.</p></disp-quote><p>As outlined above, we have identified urethral cells in our dataset. These cells cluster apart from both WT luminal progenitor and <italic>Pten<sup>fl/fl</sup></italic> intermediate cells and express urethral-specific markers (Figure 1 —figure supplement 1C-H). We have also excluded these cells from our analysis (Lines 192-193).</p><disp-quote content-type="editor-comment"><p>The key is to figure out how/why prostate luminal cells adapt to look like (and cluster with) urothelium under pten inactivation or castration (perhaps KL5? PMID: 34737261). Unfortunately, I think the leaky inactivation of Pten in basal and urethral luminal cells is confounding this question in this model. Accordingly, is there any solid evidence yet of basal epithelia acquiring mutations in human prostate cancer (notwithstanding the experimental evidence from Goldstein)?</p></disp-quote><p>We agree with the reviewer that the ubiquitous inactivation of <italic>Pten</italic> in multiple prostatic epithelial cell types in the <italic>Pten<sup>fl/fl</sup></italic> model makes it very difficult to determine how/why prostate luminal cell adapt to looks like urothelium. In order to study this, precise lineage tracing and subsequent mechanistic studies using cell-type specific models are needed to begin to understand this very interesting and confounding biology. We have now discussed these technologies in Lines 626-629 and 643-644.</p><p>As the reviewer has mentioned, human prostatic basal cells can transform into adenocarcinoma as shown by the Goldstein group using ex vivo models (Stoyanova et al., PNAS 2013). However, definitive evidence that this occurs in human tissue is currently lacking. We analyzed the basal cells in the Song et al. (Nat Comms 2022) scRNAseq dataset and found no indication of prostate cancer specific genetic lesions. However, this analysis was limited by a small sample size of n = 11. What we do know about prostatic basal cell transformation in humans can be found in case reports. It has been shown that 0.01% of human prostate cancer can present with low PSA and basal cell markers such as p63, CK5/6, and 34bE12 (Ninomiya et al., Case Reports in Oncology 2018; Dong et al., Frontiers in Oncology 2020; Shibuya et al., Molecular and Clinical Oncology 2018; Kun et al., World J Surg Oncol 2013). This is the best evidence that basal cell transformation does occur in humans. Whether transdifferentiation ensues after transformation remains to be determined.</p><disp-quote content-type="editor-comment"><p>What would be interesting is to highlight the molecular difference between lineage plastic prostate luminal cells in the castrate WT and intact Pten null mice and compare to the intact WT proximal urethral cell signature. This would give us an idea of how similar the lineage plastic state is under the 2 different conditions (I agree with your suggestion that pten inactivation could simply reduce Ar activity, making it undergo similar lineage plasticity to an 'intermediate' state). In summary, make sure to distinguish between the preexisting proximal urethral luminal cells that don't give rise to prostate luminal cells during castration/regeneration and the 'intermediate' prostate luminal cells that underwent plasticity under castration and Pten inactivation and can likely regain prostate differentiation when androgens are replenished.</p></disp-quote><p>We agree with the reviewer’s suggestion of using WT castrate mice as a comparison point with <italic>Pten<sup>fll/fl</sup></italic> intact mice. To address this question, we conducted new scRNAseq on 9 WT castrated mice, which we binned into 3 replicates, and integrated them into our existing dataset. We find that non-basal cells in WT castrate mice aggregate into one clustered region separate from both WT intact luminal cells and <italic>Pten<sup>fl/fl</sup></italic> intermediate cells (Figure 3 —figure supplement 1G). Interestingly, WT castrate (cx) luminal cells cluster closest to WT luminal progenitor cells (Figure 3 —figure supplement 1G). Computing signature scores for AR activity, translation, and proliferation between these 3 cell types reveals that WT castrate luminal cells are most similar to AR-low <italic>Pten<sup>fl/fl</sup></italic> intermediate cells, while WT intact cells share features with AR-high <italic>Pten<sup>fl/fl</sup></italic> intermediate cells (Figure 3G-H). We conclude that “intermediate-like” cells can exhibit multiple distinct states partly depending on AR activity, <italic>Pten</italic> loss, and castration status.</p><disp-quote content-type="editor-comment"><p>Figure 1: The proposition that basal cells are differentiating into intermediate luminal cells is intriguing, but could just as easily be an artifact of trajectory analysis (which is notoriously misleading) or the activation of Pten in basal epithelia (which is not yet known to happen in human prostate cancer as far as I know). It also defies the current paradigm that prostate luminal epithelia undergo lineage plasticity in castration and when mutated. Therefore, I would suggest hedging this bet in the conclusion.</p></disp-quote><p>We thank the reviewer for this suggestion. Through additional analysis, we show that intermediate cells in <italic>Pten<sup>fl/fl</sup></italic> mice represent a heterogeneous population with multiple potential cellular origins, including basal, luminal progenitor, and luminal prostate epithelial cells. In addition to our findings via trajectory analysis, RNA velocity, and Palantir (Figure 1H-J, Figure 1 —figure supplement 2C), we find that a subset of <italic>Pten<sup>fl/fl</sup></italic> intermediate cells express basal markers (Figure 3 —figure supplement 1B), supporting the hypothesis that some intermediate cells are derived from basal cell transdifferentiation. In addition, we have generated new evidence of luminal phenotype switching in our dataset. Specifically, we observe expression of multiple luminal markers in <italic>Pten<sup>fl/fl</sup></italic> intermediate cells immediately adjacent to differentiated luminal cells, suggesting that luminal cells undergo lineage plasticity to resemble intermediate cells while maintaining some identifying markers upon tumorigenesis (Figure 1 —figure supplement 2E). Finally, we show that WT intact mice contain both urethral and prostatic progenitor cells (Figure 1 —figure supplement 1C-H). Given that both proximal and distal <italic>Krt4+</italic> cells have been shown to be tumor initiating in the context of <italic>Pten</italic> loss (Guo et al., Nat Genetics 2020), it is possible that a subset of intermediate cells originated from these WT luminal progenitor cells. Given these 3 possible origins, we have updated our conclusions to reflect the multiple possible cellular origins of intermediate cell expansion in <italic>Pten<sup>fl/fl</sup></italic> mice (Lines 257-276, and 617-629).</p><disp-quote content-type="editor-comment"><p>Figure 3: While intermediate/urethral epithelia may be AR+ in WT mice, their expression of probasin and NKX3-1 is null. Thus, the AR composite score is misleading in Figure 3D. Moreover, how would the AR score be higher in intermediate/urethral epithelia than in differentiated luminal cells in WT mice??? It would seem the Hieronymus score from LNCaP cells is inappropriately used here as a measure of ALL AR activity and not a measure of prostate luminal-specific AR activity. A more accurate score would be to use probasin expression itself or a signature generated from WT vs. castrated mice (PMID: 32355025).</p></disp-quote><p>We thank the reviewer for bringing up this concern. As outlined above, we find that WT “intermediate” cells are likely not urethral in origin, and we reclassify them separately from intermediate cells as luminal progenitor cells. We have re-generated Figure 3D to include the distinction between WT luminal progenitor and <italic>Pten<sup>fl/fl</sup></italic> intermediate cells and observe that luminal progenitor cells exhibit AR activity, while total AR activity in <italic>Pten<sup>fl/fl</sup></italic> intermediate cells is low regardless of castration context (Figure 3D). This is consistent with previous studies that show unlike urethral cells, prostatic <italic>Krt4+</italic> cells express AR (Guo et al., Nat Genetics 2020; Crowley et al., <italic>eLife</italic> 2020).</p><disp-quote content-type="editor-comment"><p>The color coding of the subclustered intermediate epithelia in 3E does not seem to match the quantitation in 3F. This confuses the interpretation of 3G as well. It seems likely that the heterogeneity of cells identified as intermediate epithelia could reflect cells that are transdifferentiating from basal due to promiscuous Pten inactivation as well as from lineage plasticity of Pten inactivation in prostate luminal cells. It would be really useful to see how these clusters compare to the castrate ventral lobe in a WT mouse. It would also be useful to see the AR activity of these clusters relative to intact prostate basal and luminal cells in Figure 3G.</p></disp-quote><p>We have corrected the misaligned colors in Figure 3E-F. We agree with the reviewer that multiple cells of origin could give rise to the highly heterogeneous intermediate compartment. To investigate how the changes in intermediate cells between <italic>Pten<sup>fl/fl</sup></italic> intact and castrated mice observed in Figure 3E-G compare to a WT castrate prostate, we conducted scRNAseq of 9 castrated WT mouse prostates. The new Figure 3H shows AR activity, proliferation, and translation scores for basal and luminal cells in WT intact and castrate mice. We observe that in castration, basal cells lose proliferative capacity, while WT luminal cells lose AR activity but exhibit increased expression of translation machinery genes, most closely resembling AR-low intermediate cells in the <italic>Pten<sup>fl/fl</sup></italic> mice (Figure 3G-H). As these AR-low intermediate cells expand in <italic>Pten<sup>fl/fl</sup></italic> mice upon castration, we conclude that translational hyperactivation is likely a direct consequence of castration in the mouse prostate, which corresponds well to the observation that castration leads to increased mRNA translation in the <italic>Pten<sup>fl/fl</sup></italic> model (Liu et al., Sci Trans Med 2019). However, contrary to <italic>Pten<sup>fl/fl</sup></italic> AR-low intermediate cells, we did not observe a concomitant increase in proliferation score in WT castrate luminal cells. These findings demonstrate that castration plays an important role in translational heterogeneity in <italic>Pten<sup>fl/fl</sup></italic> intermediate cells. However, the change in proliferation is likely related to loss of <italic>Pten.</italic></p><disp-quote content-type="editor-comment"><p>I'm not sure that the observation that castration increases the number of AR-low intermediate cells necessarily means that this is a selection of a pre-existing state since we know that pre-existing prostate luminal epithelia can undergo lineage plasticity in response to castration in the non-tumorigenic setting.</p></disp-quote><p>We thank the reviewer for the intriguing suggestion that AR-low intermediate cells may represent an additional phenotype switching event. We have confirmed that AR-low, translation-high, proliferation-high cells exist in low numbers in the intact <italic>Pten<sup>fl/fl</sup></italic> mice (Figure 3F – top panel, Figure 3G). Therefore, the expansion of these cells in castrate mice is the most direct explanation for their presence. However, we recognize it is also possible that castration provokes new lineage plasticity events. Absent lineage tracing studies in vivo we cannot make conclusive statements about the precise cellular origins of hyperproliferative intermediate cells. We have updated the results and Discussion section (Lines 415-425, 640-644) to reflect this uncertainty.</p><disp-quote content-type="editor-comment"><p>The observation that the castrate Pten intermediate epithelial signature is enriched in aggressive disease (compared to intact Pten intermediate) is not too surprising as this may just reflect castration. What would be interesting is to know how this model compares to other models of castration resistance like Rb/p53 null mice.</p></disp-quote><p>We agree with the reviewer that validation of the prognostic signature in another model of castration resistance would be valuable. We have initiated a collaboration with the Rickman lab to correlate our findings with orthogonal mouse models of cancer progression and castration resistance. Specifically, we have projected our 5-gene signature of treatment resistance onto data from Brady et al. (Nat Comms 2021) using their double- and triple-mutant mice (<italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup></italic> and <italic>Pten<sup>-/-</sup>/Rb1<sup>-/-</sup>/Nmyc<sup>+</sup></italic>). The triple mutant (PRN) mice exhibit much stronger castration resistance than the double mutant (PR). Single-cell RNA sequencing data in this study was produced without castration in both PR and PRN mice, resulting in a model of cancer progression outside of physical castration. We show that our 5-gene signature is much more strongly expressed in the PRN mice compared to the PR mice, validating that the signature is enriched in a model of castration resistance (Figure 4F-G).</p><disp-quote content-type="editor-comment"><p>Discussion:</p><p>Line 488: While it's true that the transdifferentiation, an intermediate luminal phenotype is absent in the (intact) wild-type mouse, this phenotype does appear in castrate WT mice. This is not a cancer-specific lineage transition as this also happens in 5ARI-treated men (PMID 34928497).</p></disp-quote><p>We do note a shift of luminal cells in WT castrate mice towards luminal progenitors and intermediate cells, although they cluster separately from both cell states as well as proximal urethral cells (Figure 3 —figure supplement 1G). The WT castrate luminal cells cluster closest to WT intact luminal progenitor cells, indicating they may be closely related to this cell type (Figure 3 —figure supplement 1G). We have outlined observed differences between these cell types above and have updated the Results section to clarify that transdifferentiation occurs as a result of both castration and <italic>Pten</italic> loss, albeit resulting in distinct cell states (Lines 427-439).</p><disp-quote content-type="editor-comment"><p>Line 499: I'm not convinced that these data suggest that specific portions of the intermediate compartment are responsible for their expansion. Without lineage tracing in humans, it's impossible to know whether the change in heterogeneity is the result of increased transdifferentiation of both basal and luminal cells. This may be artificially induced by the promiscuous PB4-Cre promoter rather than a reflection of human prostate cancer as the level of CNVs in basal epithelia in primary tumors appears to be low.</p></disp-quote><p>We agree that the source of intermediate heterogeneity is unclear and could originate via multiple mechanisms, including additional phenotype switching events most likely in basal cells or expansion of existing cell states (Lines 415-425, 640-644). In addition, the promiscuity of the Pb-Cre transgenic system could provoke cellular events not found in humans or other systems. Further studies will be necessary to validate them in other contexts and are not within the scope of this manuscript. We have specified appropriate follow-up lineage tracing experiments in the discussion (Lines 643-644).</p><p>References</p><p>Brady NJ, Bagadion AM, Singh R, Conteduca V, Emmenis LV, Arceci E, Pakula H, Carelli R, Khani F, Bakht M, Sigouros M, Bareja R, Sboner A, Elemento O, Tagawa S, Nanus DM, Loda M, Beltran H, Robinson B, Rickman DS. 2021. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <italic>Nat Commun</italic> 12:3372. doi:10.1038/s41467-021-23780-y</p><p>Chang K, Dai B, Kong Y, Qu Y, Wu J, Ye D, Yao X, Zhang S, Zhang H, Zhu Y, Yao W. 2013. Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature. World J Surg Oncol 11:193. doi:10.1186/1477-7819-11-193</p><p>Choi N, Zhang B, Zhang L, Ittmann M, Xin L. 2012. Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation. <italic>Cancer Cell</italic> 21:253–265. doi:10.1016/j.ccr.2012.01.005</p><p>Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, Li W, Hibshoosh H, Loda M, Rabadan R, Shen MM. 2020. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. <italic>eLife</italic> 9:e59465. doi:10.7554/<italic>eLife</italic>.59465</p><p>Dong B, Miao J, Wang Y, Luo W, Ji Z, Lai H, Zhang M, Cheng X, Wang Jinming, Fang Y, Zhu HH, Chua CW, Fan L, Zhu Y, Pan J, Wang Jia, Xue W, Gao W-Q. 2020. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. <italic>Commun Biology</italic> 3:778. doi:10.1038/s42003-020-01476-1</p><p>Dong Y, Zhou L, Xia W, Zhao X-Y, Zhang Q, Jian J-M, Gao X, Wang W-P. 2020. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Initial Application of a Radiomic Algorithm Based on Grayscale Ultrasound Images. Frontiers Oncol 10:353. doi:10.3389/fonc.2020.00353</p><p>Guo W, Li L, He J, Liu Z, Han M, Li F, Xia X, Zhang X, Zhu Y, Wei Y, Li Y, Aji R, Dai H, Wei H, Li C, Chen Y, Chen L, Gao D. 2020. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. <italic>Nat Genet</italic> 52:908–918. doi:10.1038/s41588-020-0642-1</p><p>Korsten H, Made AZ der, Ma X, Kwast T van der, Trapman J. 2009. Accumulating Progenitor Cells in the Luminal Epithelial Cell Layer Are Candidate Tumor Initiating Cells in a Pten Knockout Mouse Prostate Cancer Model. <italic>Plos One</italic> 4:e5662. doi:10.1371/journal.pone.0005662</p><p>Kwon O, Zhang L, Xin L. 2016. Stem Cell Antigen‐1 Identifies a Distinct Androgen‐Independent Murine Prostatic Luminal Cell Lineage with Bipotent Potential. <italic>Stem Cells</italic> 34:191–202. doi:10.1002/stem.2217</p><p>Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. 2019. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. <italic>Sci Transl Med</italic> 11:eaaw4993. doi:10.1126/scitranslmed.aaw4993</p><p>Lu T-L, Huang Y-F, You L-R, Chao N-C, Su F-Y, Chang J-L, Chen C-M. 2013. Conditionally Ablated Pten in Prostate Basal Cells Promotes Basal-to-Luminal Differentiation and Causes Invasive Prostate Cancer in Mice. <italic>Am J Pathology</italic> 182:975–991. doi:10.1016/j.ajpath.2012.11.025</p><p>Network TCGAR, 2015. The Molecular Taxonomy of Primary Prostate Cancer. <italic>Cell</italic> 163:1011–1025. doi:10.1016/j.cell.2015.10.025</p><p>Ninomiya S, Kawahara T, Iwashita H, Iwamoto G, Takamoto D, Mochizuki T, Kuroda S, Takeshima T, Izumi K, Teranishi J, Yumura Y, Miyoshi Y, Asai T, Uemura H. 2018. Prostate Basal Cell Carcinoma: A Case Report. Case Reports Oncol 11:138–142. doi:10.1159/000487389</p><p>Sala LS, Boutillon F, Menara G, Goyon‐Pélard AD, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole‐Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti J, Goffin V. 2017. A rare castration‐resistant progenitor cell population is highly enriched in Pten‐null prostate tumours. <italic>J Pathology</italic> 243:51–64. doi:10.1002/path.4924</p><p>Shibuya K, Homma S, Yoshida T, Ohno Y, Ichikawa N, Kawamura H, Imamoto T, Matsuno Y, Taketomi A. 2018. Carcinoma in the residual rectum of a long-standing Crohn’s disease patient following subtotal colectomy: A case report. Mol Clin Oncol 9:50–53. doi:10.3892/mco.2018.1626</p><p>Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. 2022. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. <italic>Nat Commun</italic> 13:141. doi:10.1038/s41467-021-27322-4</p><p>Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora Vivek K., Kaushik Poorvi, Cerami Ethan, Reva Boris, Antipin Yevgeniy, Mitsiades Nicholas, Landers Thomas, Dolgalev Igor, Major John E., Wilson Manda, Socci Nicholas D., Lash Alex E., Heguy Adriana, Eastham James A., Scher Howard I., Reuter Victor E., Scardino Peter T., Sander Chris, Sawyers Charles L., Gerald WL. 2010. Integrative Genomic Profiling of Human Prostate Cancer. <italic>Cancer Cell</italic> 11–22. doi:10.1016/j.ccr.2010.05.026</p><p>Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM. 2013. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. <italic>Nat Cell Biol</italic> 15:274–283. doi:10.1038/ncb2697</p><p>Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. <italic>P Natl Acad Sci Usa</italic> 103:1480–1485. doi:10.1073/pnas.0510652103</p><p>Xin L, Lawson DA, Witte ON. 2005. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. <italic>PNAS</italic> 102:6942–6947. doi:10.1073/pnas.0502320102</p></body></sub-article></article>